toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context,filter_reason
tyrosine hydroxylase,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,tyrosine hydroxylase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000) | Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000),Antibody target not in NF pathway/tumor biology gene list: tyrosine hydroxylase
GFP,antibodies,PMID:34415582 | PMID:41022755 | PMID:40590220 | PMID:31545171 | PMID:31015291 | PMID:32461556 | PMID:29715273 | PMID:36890585 | PMID:34257279,10.1002/glia.24075 | 10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1126/scisignal.aau8749 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1186/s40478-023-01525-w | 10.1038/s41467-021-24505-x,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.95,Experimental Usage,False,0.67,Low,,,,GFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used in this study: Rabbit anti-GFP, Thermo Fisher, Cat. # A6455 (1/1000) | rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies | Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals | GFP (ab1218, Abcam, Western blotting and Invitrogen, IP) | Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000) | Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland | GFP Life Technologies, A11122 1:1000 Overnight, RT Citrate buffer, pH 6.0 | anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany) | chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK) | Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)",Generic reporter/tag/housekeeping antibody: gfp
TRIM23,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,TRIM23,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical stain for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal)",Antibody target not in NF pathway/tumor biology gene list: TRIM23
H3K27me3,antibodies,PMID:32642734 | PMID:31462295 | PMID:39321200 | PMID:30479396 | PMID:38127282 | PMID:38216572 | PMID:37246765 | PMID:36598417,10.1093/noajnl/vdz026 | 10.1186/s40478-019-0792-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/2159-8290.CD-22-0786,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.95,Experimental Usage,False,1.00,Medium,,,,H3K27me3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50 dilution; Cell Signaling Technology) | using a mouse monoclonal antibody (Abcam, Cat# ab6002, Cambridge, MA) at 1:1600 dilution | IHC for H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:100 dilution) was performed on FFPE whole slide tissue sections | H3K27Me3 (Cell Signaling, 9733 S, 1:500) | H3K27me3 (9733S, 1:100, Cell Signaling) | H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:50 dilution) | H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: H3K27me3
Cleaved-caspase 3,antibodies,PMID:32642734 | PMID:32461556 | PMID:38502231 | PMID:24509877 | PMID:36322658 | PMID:34040258 | PMID:35511749 | PMID:26904939 | PMID:36241865 | PMID:24817309,10.1093/noajnl/vdz026 | 10.1038/s41467-020-16432-0 | 10.1172/JCI176748 | 10.1038/onc.2013.506 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1158/1535-7163.MCT-21-0947 | 10.1016/j.celrep.2016.01.074 | 10.1038/s12276-022-00850-9 | 10.1371/journal.pone.0097320,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,Experimental Usage,False,0.33,Low,,,,Cleaved-caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for Cleaved-caspase 3 at 1:500 (Cell Signaling Technology, Danvers, MA) | Cleaved Caspase-3 (D175) Cell Signaling Technology, #9661L 1:500 Overnight, RT Citrate buffer, pH 6.0 | cleaved caspase 3 (9661S, Cell Signaling Technology) | Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako), MBP (Chemicon), BLBP (Millipore), DEPTOR (Novus), cleaved-caspase 3 | cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661), BrdU (rat; Abcam, ab6326) | rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A | Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology | anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA) | Anti-cleaved caspase-3 antibody primary IF and WB CST | cleaved caspase-3+ cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)",Antibody target not in NF pathway/tumor biology gene list: Cleaved-caspase 3
Ki67,antibodies,PMID:40394150 | PMID:32699356 | PMID:32948135 | PMID:32642734 | PMID:35589737 | PMID:19191334 | PMID:32461556 | PMID:29715273 | PMID:34040258 | PMID:35945463 | PMID:29941005 | PMID:29438698 | PMID:24681606 | PMID:30055648 | PMID:33032988 | PMID:26904939 | PMID:40684195 | PMID:32642733 | PMID:36148553 | PMID:33356508 | PMID:37246765 | PMID:24371224 | PMID:25535838 | PMID:33591953 | PMID:38945076 | PMID:34930951 | PMID:39996452 | PMID:21216928,10.1038/s41416-025-03055-9 | 10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1093/noajnl/vdz026 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1038/s41586-021-03580-6 | 10.1007/s00401-022-02478-5 | 10.1186/s13023-018-0843-1 | 10.1016/j.ccell.2018.01.005 | 10.18632/oncotarget.1609 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-20-1365 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1093/noajnl/vdz061 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151 | 10.1172/jci.insight.146351 | 10.1016/j.redox.2024.103249 | 10.1038/s41536-021-00195-3 | 10.1111/cns.70287 | 10.1158/1535-7163.MCT-10-0654,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin. | Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ki67,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)... | mouse anti-Ki67 (550609, 1:500, BD Pharmingen) | proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO) | prediluted Ki67 (790–4286; Ventana) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Ki-67 (BD Pharmingen, San Diego, CA) antibodies followed by Vectastain ABC development | KI67 Monosan, MONX10283 1:2000 Overnight, RT Citrate buffer, pH 6.0 | anti Ki67 (15580, 1:500, Abcam, Cambridge, UK) | using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549) | Ki-67 (Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval) | ...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)... | Ki67 (Rabbit; Thermo Fisher Scientific, RM-9106), BrdU (Rat; Abcam, ab6326) | primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200)) | anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9) to evaluate proliferation fraction | Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam) | Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL) | rabbit anti-Ki67 (1:200; Abcam #ab15580) | Ki67 (Ventana Medical Systems) | Ki67 (1:100; ab15580; Abcam) | Ki67-FITC (proliferation marker) | Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology) | Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako) | Ki-67 (1:500, mouse, BD Pharmingen) | staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam), KI-67 (prediluted; catalog 790-4286, Ventana) | Cells were stained with antibodies specific for Ki-67 (1:800 dilution, Cat. no. 9449, Cell Signaling) | examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam. | immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described",Antibody target not in NF pathway/tumor biology gene list: Ki67
GFAP,antibodies,PMID:32699356 | PMID:18451155 | PMID:35589737 | PMID:19191334 | PMID:35945463 | PMID:20554030 | PMID:33356508 | PMID:25535838 | PMID:34930951 | PMID:25772366 | PMID:36241865 | PMID:20551058 | PMID:19144871,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1177/0963689720964383 | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1016/j.celrep.2015.02.041 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769 | 10.3181/0809-RM-275,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.95,Experimental Usage,False,1.00,Medium,,,,GFAP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen) | β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO) | Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA) | glial fibrillary acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval) | Invitrogen (Rat anti-GFAP) | labeled overnight at room temperature with the following conjugated primary antibodies: S100-FITC, Vimentin-FTIC, CD45-APC, Ki67-APC, and GFAP-APC | GFAP (1:2000, rabbit, DAKO, Carpinteria, CA) | Every 6th section was stained with GFAP-PE (Muller cells marker) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte) | Anti-GFAP antibody primary IF and WB CST | Invitrogen (GFAP) | mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA)",Antibody target not in NF pathway/tumor biology gene list: GFAP
Iba-1,antibodies,PMID:36890585 | PMID:35589737 | PMID:38502231 | PMID:36322658 | PMID:34040258 | PMID:37990867 | PMID:20554030 | PMID:34930951 | PMID:20551058,10.1186/s40478-023-01525-w | 10.1038/s41467-022-30466-6 | 10.1172/JCI176748 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1242/dmm.049861 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/s41536-021-00195-3 | 10.1158/0008-5472.CAN-09-3769,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.95,Experimental Usage,False,0.67,Low,,,,Iba-1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Iba1 (019-19741, Thermo Fisher Scientific) | IBA1 (rabbit; Wako Chemicals, 019-19741), CD3 (rat; Bio-Rad, MCA1477) | rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4) | Cells were next stained with anti-IBA1 antibody (Table S1) in TBS containing 5% donkey serum overnight | Wako (rabbit anti-IBA-1) | CD45-PE, IBA1-FITC (immune cell marker) | Wako (IBA-1)",Antibody target not in NF pathway/tumor biology gene list: Iba-1
SOX10,antibodies,PMID:38907342 | PMID:37770931 | PMID:35589737 | PMID:35945463 | PMID:38216587 | PMID:29438698 | PMID:38744290 | PMID:38216572 | PMID:36598417 | PMID:39415595,10.1186/s40478-024-01821-z | 10.1186/s40478-023-01639-1 | 10.1038/s41467-022-30466-6 | 10.1007/s00401-022-02478-5 | 10.1038/s41467-023-40408-5 | 10.1016/j.ccell.2018.01.005 | 10.1016/j.crmeth.2024.100772 | 10.1038/s41467-024-44755-9 | 10.1158/2159-8290.CD-22-0786 | 10.1242/dmm.050862,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.",,0.95,Experimental Usage,False,0.33,Low,,,,SOX10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 at 1:500 dilution (abcam Cat # ab155279) for Schwann cells | SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | SOX10 (Cell Marque, clone EP268, dilution 1:250, ER2 antigen retrieval) | labeled with primary antibodies including SOX10 to mark schwannoma cells (API 3099, Biocare; labeling validated in schwannoma and melanoma) | Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P) | SOX10 Biocare Medical CAT#ACI3099A | SOX10 (Cell Marque, #383R-1, clone EP268, 1:50 dilution) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10) | Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021)",Antibody target not in NF pathway/tumor biology gene list: SOX10
Rbpms,antibodies,PMID:35589737 | PMID:34930951,10.1038/s41467-022-30466-6 | 10.1038/s41536-021-00195-3,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,False,0.33,Low,,,,Rbpms,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1 | labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC, RBPMS-APC",Antibody target not in NF pathway/tumor biology gene list: Rbpms
Tuj-1,antibodies,PMID:35589737 | PMID:23328114 | PMID:25772366,10.1038/s41467-022-30466-6 | 10.18632/oncotarget.793 | 10.1016/j.celrep.2015.02.041,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,0.33,Low,,,,Tuj-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1 | Tuj1 (Covance) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",Antibody target not in NF pathway/tumor biology gene list: Tuj-1
Peripherin,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,Peripherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: Peripherin
ISL1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,ISL1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1",Antibody target not in NF pathway/tumor biology gene list: ISL1
Krox20,antibodies,PMID:28465357 | PMID:29438698,10.1101/gad.298703.117 | 10.1016/j.ccell.2018.01.005,Identification of hair shaft progenitors that create a niche for hair pigmentation. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,Krox20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074) | Krox20 (Rabbit; Covance, PRB-236P), MBP (Goat; Santa Cruz Biotechnology, sc-13914)",Antibody target not in NF pathway/tumor biology gene list: Krox20
pERα S118,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,pERα S118,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERα S118 (Sigma, Cat# SAB450399)",Antibody target not in NF pathway/tumor biology gene list: pERα S118
pERK T202/Y204,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.33,Low,,,,pERK T202/Y204,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)",Antibody target not in NF pathway/tumor biology gene list: pERK T202/Y204
pAKT S473,antibodies,PMID:38216123 | PMID:24681606,10.1016/j.molmet.2024.101876 | 10.18632/oncotarget.1609,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.33,Low,,,,pAKT S473,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT S473 (Cell Signaling Technology, Cat#9271L) | The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100)",Antibody target not in NF pathway/tumor biology gene list: pAKT S473
β-tubulin,antibodies,PMID:33078583 | PMID:38216123 | PMID:39129390 | PMID:34257279 | PMID:18367665,10.1002/jcsm.12632 | 10.1016/j.molmet.2024.101876 | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1124/jpet.107.135830,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,Experimental Usage,False,0.67,Low,,,,β-tubulin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-β-tubulin (Sigma-Aldrich T8328) | β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000) | anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1 : 10 000) | anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000) | β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)",Generic reporter/tag/housekeeping antibody: β-tubulin
BRN3A,antibodies,PMID:34040258 | PMID:34930951,10.1038/s41586-021-03580-6 | 10.1038/s41536-021-00195-3,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,False,1.00,Medium,,,,BRN3A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718) | labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC",Antibody target not in NF pathway/tumor biology gene list: BRN3A
Caspase9,antibodies,PMID:34930951 | PMID:23328114,10.1038/s41536-021-00195-3 | 10.18632/oncotarget.793,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,Caspase9,,,,,,,,,,,,,,,,,,,,,,,,,,,,Caspase9-FITC (apoptosis marker) | caspase 9 (Cell Signalling),Antibody target not in NF pathway/tumor biology gene list: Caspase9
NeuN,antibodies,PMID:36890585 | PMID:25535838 | PMID:34930951 | PMID:36241865,10.1186/s40478-023-01525-w | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1038/s12276-022-00850-9,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,0.67,Low,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-NeuN targeting neurons (1:00; Synaptic Systems) | NeuN (1:400, mouse, Millipore, Billerica, MA) | NeuN-APC (neuronal marker) | Anti-NeuN antibody primary IF and WB CST",Antibody target not in NF pathway/tumor biology gene list: NeuN
CD45,antibodies,PMID:40217315 | PMID:30479396 | PMID:29941005 | PMID:34010628 | PMID:40684195 | PMID:33356508 | PMID:34930951,10.1186/s13073-025-01462-4 | 10.1038/s41467-018-07452-y | 10.1186/s13023-018-0843-1 | 10.1016/j.stem.2021.04.029 | 10.1186/s40478-025-02075-z | 10.1177/0963689720964383 | 10.1038/s41536-021-00195-3,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.95,Experimental Usage,False,0.67,Low,,,,CD45,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C. | CD45 [eBioscience; cat. no. 25-0451-82; 1:100] | ...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA)... | endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 103112) | goat anti-CD45 (1:100; Bio-Techne #AF114) | Foxp3-APC and CD45 (immune response markers) | Every 5th section was stained with CD45-PE, IBA1-FITC (immune cell marker)",Antibody target not in NF pathway/tumor biology gene list: CD45
HLA-DR,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,HLA-DR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: HLA-DR
CD33,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD33,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD33 APC (eBioscience, 0.125 µg/test)",Antibody target not in NF pathway/tumor biology gene list: CD33
CD11b,antibodies,PMID:30542164 | PMID:38907342 | PMID:41149489 | PMID:36890585 | PMID:28256556,10.1038/s41586-018-0774-y | 10.1186/s40478-024-01821-z | 10.3390/curroncol32100569 | 10.1186/s40478-023-01525-w | 10.1038/srep43315,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.",,0.95,Experimental Usage,False,0.33,Low,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibody, anti-CD11b (1:8000 dilution; catalogue number ab133357, Abcam) was applied at 36 °C for 40 min. | CD11b at 1:100 dilution (abcam Cat # ab52478) for myeloid cells | anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test) | incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) | anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)",Antibody target not in NF pathway/tumor biology gene list: CD11b
CD9,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)",Antibody target not in NF pathway/tumor biology gene list: CD9
CD81,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.33,Low,,,,CD81,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD81 (Proteintech, 66866-1-Ig)",Antibody target not in NF pathway/tumor biology gene list: CD81
TOMM20,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,False,0.67,Low,,,,TOMM20,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"TOMM20 (Proteintech, 11802-1-AP)",Antibody target not in NF pathway/tumor biology gene list: TOMM20
HSP90,antibodies,PMID:41149489 | PMID:27956228,10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.67,Low,,,,HSP90,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"HSP90 (Proteintech, 13171-1-AP) | 1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",Antibody target not in NF pathway/tumor biology gene list: HSP90
AKT,antibodies,PMID:36730269 | PMID:41149489 | PMID:33273014 | PMID:29847659 | PMID:20554030 | PMID:26219339 | PMID:21072183 | PMID:18483311 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1074/jbc.RA120.014960 | 10.1167/iovs.17-22588 | 10.1016/j.jneuroim.2010.05.002 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791 | 10.1158/1535-7163.MCT-07-2335 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.95,Experimental Usage,False,0.33,Low,,,,AKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total AKT (Catalogue # 4691) | AKT (CST, #9272S, Danvers, MA, USA) | Antibodies recognizing... Akt T308, Akt, p70S6K T389... were from Cell Signaling | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT) | Akt, phospho-NDRG1 (T346), SGK1 | The antibodies used in this study include... Akt... (Cell Signaling Technology) | Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology | total AKT (Cell Signaling Technologies, # 4685, 1:1000 dilution) | Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Antibody target not in NF pathway/tumor biology gene list: AKT
pAKT,antibodies,PMID:33442015 | PMID:36730269 | PMID:41149489 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1038/s41591-020-01193-6 | 10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.95,Experimental Usage,False,0.33,Low,,,,pAKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology) | pAKT (Catalogue # 4060) | p-AKT (CST, #4051S) | pAKT (Cell Signaling Technologies, #4060, 1:1000 dilution) | Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",Antibody target not in NF pathway/tumor biology gene list: pAKT
ERK,antibodies,PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:38714355 | PMID:38216572 | PMID:18413802,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41467-024-44755-9 | 10.1158/1535-7163.MCT-07-0518,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.95,Experimental Usage,False,0.33,Low,,,,ERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (Catalogue # 9102) | total ERK (Cell Signaling cat# 9102 1:1000) | ERK (CST, #4695) | total ERK (rabbit, CST 9102, Danvers, MA USA, 1 : 1000) | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | total ERK (rabbit, CST 9102, 1:1000) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | total ERK (Cell Signaling Technologies, #4695, 1:1000 dilution) | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: ERK
p-Erk,antibodies,PMID:32699356 | PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:27956228 | PMID:24509877 | PMID:24681606 | PMID:28166733 | PMID:40684195 | PMID:38216572 | PMID:37246765 | PMID:24371224 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.18632/oncotarget.1609 | 10.1186/s12864-017-3519-7 | 10.1186/s40478-025-02075-z | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p-Erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling) | The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370) | p-ERK (Cell Signaling cat# 9101 1:1000) | p-ERK (CST, #9101S) | 1:1000 anti-pErk (Cell Signaling) | Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus) | p-ERK (Cell Signaling 1:1000) | p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C) | rabbit anti-P-ERK (1:250; Cell Signaling #9101) | pERK (Cell Signaling Technologies, #4370, 1:1000 dilution) | H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies) | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz | p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: p-Erk
ERK1/2,antibodies,PMID:41022755 | PMID:40590220 | PMID:21072183 | PMID:29670214 | PMID:37681415 | PMID:25043591 | PMID:20200958 | PMID:24375753,10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.1371/journal.pone.0013791 | 10.1038/s41598-018-24310-5 | 10.1172/jci.insight.168445 | 10.1002/jbmr.2316 | 10.1002/jbmr.42 | 10.1002/ana.24093,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Restoring functional neurofibromin by protein transduction. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-ERK1/2 (p44/42 MAPK) antibody (#9102) | ERK1/2 (9102, Cell Signaling Technology) | The antibodies used in this study include... Erk1/2... (Cell Signaling Technology) | Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000) | ERK1/2 (CST 9107, clone 3A7) | ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000) | Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies | pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: ERK1/2
phospho-ERK1/2,antibodies,PMID:41022755 | PMID:24932921 | PMID:33436083 | PMID:33934112 | PMID:29670214 | PMID:25043591 | PMID:20200958,10.1038/s41467-025-63619-4 | 10.1002/jbmr.2298 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03716-6 | 10.1038/s41598-018-24310-5 | 10.1002/jbmr.2316 | 10.1002/jbmr.42,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Restoring functional neurofibromin by protein transduction. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.95,Experimental Usage,False,1.00,Medium,,,,phospho-ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101) | The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA) | phospho-ERK1/2 (Cell Signaling #9101) | rabbit polyclonal anti-phospho-ERK1/2 was from Cell Signaling (Cat. #9101) | anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000) | using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000) | Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK1/2
Flag,antibodies,PMID:40590220 | PMID:36420221 | PMID:31836666 | PMID:24595234 | PMID:36689660 | PMID:40225167 | PMID:16835260,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.1074/jbc.RA119.010934 | 10.1371/journal.pone.0090853 | 10.1073/pnas.2208960120 | 10.1155/2023/9628049 | 10.1093/hmg/ddl165,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.95,Experimental Usage,False,0.33,Low,,,,Flag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Flag (F7425, MilliporeSigma) | Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO) | Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793) | Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000 | Supernatants from cleared lysates were incubated with Anti-FLAG M2 affinity gel (Sigma) to immunoprecipitated FLAG-tagged protein complexes | Primary antibodies used were FLAG-M2 and KRAS (Sigma) | Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences | equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)",Generic reporter/tag/housekeeping antibody: flag
V5,antibodies,PMID:31836666 | PMID:40225167,10.1074/jbc.RA119.010934 | 10.1155/2023/9628049,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,V5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were V5 (rabbit, 13202) | Invitrogen (mouse anti-V5), Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",Generic reporter/tag/housekeeping antibody: v5
HA,antibodies,PMID:41022755 | PMID:31836666 | PMID:40225167 | PMID:36689660,10.1038/s41467-025-63619-4 | 10.1074/jbc.RA119.010934 | 10.1155/2023/9628049 | 10.1073/pnas.2208960120,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.95,Experimental Usage,False,1.00,Medium,,,,HA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-HA antibody (26183) was purchased from Invitrogen | Primary antibodies (Cell Signaling Technology) used for Western blotting were HA (rabbit, 3724) | Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc) | HA, HSP70, and Ubiquitin (Cell Signaling)",Generic reporter/tag/housekeeping antibody: ha
pEGFR,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.33,Low,,,,pEGFR,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Western blots to verify protein expression levels were run on Tris acetate or Bolt gels and probed with a series of antibodies: pEGFR (Cell Signaling 3777),Antibody target not in NF pathway/tumor biology gene list: pEGFR
KRAS,antibodies,PMID:31836666 | PMID:37681415 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1172/jci.insight.168445 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,False,0.67,Low,,,,KRAS,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1) | KRAS (Sigma; WH0003845M1, clone 3B10-2F2; does not detect proteins with E162L mutation) | Primary antibodies used were FLAG-M2 and KRAS (Sigma)",Antibody target not in NF pathway/tumor biology gene list: KRAS
collagen IV,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,collagen IV,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500),Antibody target not in NF pathway/tumor biology gene list: collagen IV
MyHC type 1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500),Antibody target not in NF pathway/tumor biology gene list: MyHC type 1
MyHC type 2A,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 2A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200),Antibody target not in NF pathway/tumor biology gene list: MyHC type 2A
laminin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,laminin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500),Antibody target not in NF pathway/tumor biology gene list: laminin
Pax7,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,Pax7,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-Pax7 (DSHB Pax7; 1:10),Antibody target not in NF pathway/tumor biology gene list: Pax7
myosin heavy chain,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,myosin heavy chain,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000),Antibody target not in NF pathway/tumor biology gene list: myosin heavy chain
beta III tubulin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,beta III tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500),Antibody target not in NF pathway/tumor biology gene list: beta III tubulin
perilipin A/B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,perilipin A/B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250),Antibody target not in NF pathway/tumor biology gene list: perilipin A/B
PPARG,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,PPARG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443),Antibody target not in NF pathway/tumor biology gene list: PPARG
phosphor (pThr172) AMPKa,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (pThr172) AMPKa,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),Antibody target not in NF pathway/tumor biology gene list: phosphor (pThr172) AMPKa
AMPKα,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,AMPKα,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-AMPKα (Cell Signaling Technology 2532),Antibody target not in NF pathway/tumor biology gene list: AMPKα
phosphor (s235/236) S6,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (s235/236) S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),Antibody target not in NF pathway/tumor biology gene list: phosphor (s235/236) S6
MyHC type 2B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,1.00,Medium,,,,MyHC type 2B,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2B (DSHB BF-F3),Antibody target not in NF pathway/tumor biology gene list: MyHC type 2B
phosphor (Ser473) AKT,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphor (Ser473) AKT,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phosphor (Ser473) AKT
phospho (Ser1101) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phospho (Ser1101) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phospho (Ser1101) IRS-1
phospho (Ser636/639) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.67,Low,,,,phospho (Ser636/639) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)",Antibody target not in NF pathway/tumor biology gene list: phospho (Ser636/639) IRS-1
DIG-Fab,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,False,0.33,Low,,,,DIG-Fab,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)",Generic reporter/tag/housekeeping antibody: dig-fab
RAS,antibodies,PMID:38201517 | PMID:18367665 | PMID:18413802 | PMID:36689660,10.3390/cancers16010089 | 10.1124/jpet.107.135830 | 10.1158/1535-7163.MCT-07-0518 | 10.1073/pnas.2208960120,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.95,Experimental Usage,False,1.00,Medium,,,,RAS,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002). | Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA) | Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody | pan-RAS (Abcam)",Antibody target not in NF pathway/tumor biology gene list: RAS
N-RAS,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,N-RAS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519).",Antibody target not in NF pathway/tumor biology gene list: N-RAS
RAB5A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,,,,RAB5A,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309).",Antibody target not in NF pathway/tumor biology gene list: RAB5A
RAP1A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,0.67,Low,,,,RAP1A,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482).",Antibody target not in NF pathway/tumor biology gene list: RAP1A
MYF-4,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,MYF-4,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",Antibody target not in NF pathway/tumor biology gene list: MYF-4
S100,antibodies,PMID:24040940 | PMID:25851896 | PMID:30479396 | PMID:24681606 | PMID:40025578 | PMID:30055648 | PMID:18636037 | PMID:38744290 | PMID:36148553 | PMID:33356508 | PMID:41001593 | PMID:33591953 | PMID:36598417 | PMID:21111000 | PMID:33767727 | PMID:15255999 | PMID:15240917 | PMID:19144871,10.1186/1479-5876-11-213 | 10.3988/jcn.2015.11.2.172 | 10.1038/s41467-018-07452-y | 10.18632/oncotarget.1609 | 10.1186/s40478-025-01965-6 | 10.1186/s13104-018-3630-0 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.crmeth.2024.100772 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1080/23723556.2025.2561292 | 10.1172/jci.insight.146351 | 10.1158/2159-8290.CD-22-0786 | 10.1016/j.jneumeth.2010.10.021 | 10.3389/fgene.2021.603195 | 10.1186/1476-4598-3-20 | 10.1155/S1110724304308107 | 10.3181/0809-RM-275,"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | A novel imaging-compatible sciatic nerve schwannoma model. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing. | Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. | Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.",,0.95,Experimental Usage,False,0.33,Low,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution | cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark) | S100 (DAKO, Z0311, 1:5000) | primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200)) | rabbit anti-human S100 (ZSGB-BIO, ZA-0225) | antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9) to demonstrate human Schwann cell origin | rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO) | S100 Biocare Medical CAT#ACI3237A | S100 (pre-diluted; GA504; Dako) | incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells) | S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000 | IHC was performed using the Avidin/Biotin blocking kit (Vector Labs, SP-2001) staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10) | S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry | Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei | They were all S100-positive by immunostaining. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining | Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif) | The following primary antibodies were used: rabbit anti-NF2 (Santa Cruz); mouse anti-p55 monoclonal (this study); mouse anti-S100 (SIGMA)",Antibody target not in NF pathway/tumor biology gene list: S100
HMB45,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,HMB45,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,Antibody target not in NF pathway/tumor biology gene list: HMB45
Melan-A,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,0.33,Low,,,,Melan-A,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,Antibody target not in NF pathway/tumor biology gene list: Melan-A
CD90,antibodies,PMID:29941005 | PMID:25851896,10.1186/s13023-018-0843-1 | 10.3988/jcn.2015.11.2.172,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD90,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend)... | cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany)",Antibody target not in NF pathway/tumor biology gene list: CD90
S100B,antibodies,PMID:41022755 | PMID:38175707 | PMID:41444363 | PMID:38216572 | PMID:37246765 | PMID:39110684 | PMID:34646065,10.1038/s41467-025-63619-4 | 10.1172/jci.insight.168826 | 10.1038/s41598-025-32031-9 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1371/journal.pone.0308207 | 10.1155/2021/9386823,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers. | Survival and,,0.95,Experimental Usage,False,1.00,Medium,,,,S100B,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-S100B antibody (Z0311) was purchased from DAKO | incubated with primary antibodies, p75 (1:100, Ab3125, Abcam), S100B (1:1,000, Z0311, Dako) | Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein | S100B (Ventana, #760-2523, 1:2 dilution) | Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology) | Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio | immunohistochemical S100 B data from a pathology service...An S100 B immunonegative tumor phenotype was associated with a significantly worse outcome",Antibody target not in NF pathway/tumor biology gene list: S100B
beta-Catenin,antibodies,PMID:27956228 | PMID:24371224,10.1053/j.gastro.2016.12.002 | 10.1158/0008-5472.CAN-13-2062,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,beta-Catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: beta-Catenin
SOX9,antibodies,PMID:27956228 | PMID:24509877 | PMID:20049725 | PMID:32396062,10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.7554/eLife.55137,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,0.33,Low,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences) | Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako) | probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700) | We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK) | Antibody anti-SOX9, rabbit polyclonal Millipore Sigma Cat. # AB5535 RRID: AB_2239761 1/500 dilution",Antibody target not in NF pathway/tumor biology gene list: SOX9
collagen XV,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,False,0.67,Low,,,,collagen XV,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000)...",Antibody target not in NF pathway/tumor biology gene list: collagen XV
collagen XVIII,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,False,0.67,Low,,,,collagen XVIII,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody...",Antibody target not in NF pathway/tumor biology gene list: collagen XVIII
K1,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K1 (BioLegend, 905601, 1:100)",Antibody target not in NF pathway/tumor biology gene list: K1
LUMICAN,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.33,Low,,,,LUMICAN,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LUMICAN (Santa Cruz; sc-166871, 1:200)",Antibody target not in NF pathway/tumor biology gene list: LUMICAN
CD3,antibodies,PMID:30542164 | PMID:30479396 | PMID:38502231 | PMID:30531922 | PMID:36322658 | PMID:38216587 | PMID:39321200 | PMID:37410426,10.1038/s41586-018-0774-y | 10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1038/s41591-018-0263-8 | 10.1126/sciadv.abo5442 | 10.1038/s41467-023-40408-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.95,Experimental Usage,False,0.67,Low,,,,CD3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell. | precoated with indicated doses of anti-CD3 Ab (eBioscience; cat. no. 16-0031-86) | CD3 (ab16669, Abcam) | Primary antibodies were incubated at 4 °C overnight: CD3 (Dako, A0452, 1:200) | CD3 (rat; Bio-Rad, MCA1477), GLUT1 (rabbit; Abcam, ab652) | slides were subjected to antigen retrieval and labeled with CD3 (A0452, Agilent Technologies, Santa Clara, CA; labeling validated by over-expression) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3... | CD3 to identify T cells (rabbit monoclonal, NeoMarkers Company, #RM-9107-S, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD3
CD28,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.67,Low,,,,CD28,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),Antibody target not in NF pathway/tumor biology gene list: CD28
CD69,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,0.67,Low,,,,CD69,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85; 1:100),Antibody target not in NF pathway/tumor biology gene list: CD69
CD4,antibodies,PMID:30479396 | PMID:38502231 | PMID:40025578,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1186/s40478-025-01965-6,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4 [eBioscience; cat. no. 17-0042-83; 1:100] | CD4 (ab183685, Abcam) | HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",Antibody target not in NF pathway/tumor biology gene list: CD4
CD8,antibodies,PMID:30479396 | PMID:30531922 | PMID:34040258 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1038/s41591-018-0263-8 | 10.1038/s41586-021-03580-6 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8 [Lifetech; cat. no. A15836; 1:100] | CD8 (Leica NCL-L-CD8–4B11, 1:200) | rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD8
FoxP3,antibodies,PMID:30479396 | PMID:38502231 | PMID:33356508 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1177/0963689720964383 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,FoxP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FoxP3 [eBioscience; cat. no. 12-57773-80; 1:100] | Foxp3 (ab215206, Abcam) | Foxp3-APC and CD45 (immune response markers) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: FoxP3
B220,antibodies,PMID:30479396 | PMID:37410426,10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-0749,"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.33,Low,,,,B220,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"B220 [eBioscience; cat. no. 11-0452-85; 1:100] | B220 to identify B cells (RRID: AB_323211, rat anti-mouse monoclonal, Serotec Company, Catalog #MCA1258G, 1:1200)",Antibody target not in NF pathway/tumor biology gene list: B220
MIA,antibodies,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,MIA,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40",Antibody target not in NF pathway/tumor biology gene list: MIA
AQP4,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,AQP4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: AQP4
NG2,antibodies,PMID:36730269 | PMID:19191334,10.1371/journal.pone.0277305 | 10.1002/glia.20845,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.95,Experimental Usage,False,0.33,Low,,,,NG2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NG2 (Catalogue # PA5-17199) from Invitrogen | AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: NG2
O4,antibodies,PMID:19191334 | PMID:25772366,10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,0.33,Low,,,,O4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",Antibody target not in NF pathway/tumor biology gene list: O4
LHX2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,LHX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",Antibody target not in NF pathway/tumor biology gene list: LHX2
APC,antibodies,PMID:19191334 | PMID:37164978,10.1002/glia.20845 | 10.1038/s41467-023-38432-6,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,APC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"APC (Calbiochem; San Diego, CA) | APC(1:500, Cat #15270, Abcam)",Antibody target not in NF pathway/tumor biology gene list: APC
FOXG1,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXG1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: FOXG1
FOXP2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: FOXP2
HOXB3,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,0.33,Low,,,,HOXB3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: HOXB3
GLAST,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,Experimental Usage,False,0.33,Low,,,,GLAST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GLAST (a gift from Dr. Watanabe; (Shibata et al. 1997)),Antibody target not in NF pathway/tumor biology gene list: GLAST
RFP,antibodies,PMID:31015291 | PMID:40684195,10.1126/scisignal.aau8749 | 10.1186/s40478-025-02075-z,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,RFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,specific for RFP (cat no. ab34767) was from Abcam | rabbit anti-RFP (1:1000; Rockland #600-401-379),Generic reporter/tag/housekeeping antibody: rfp
MYC,antibodies,PMID:36730269 | PMID:40225167,10.1371/journal.pone.0277305 | 10.1155/2023/9628049,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.95,Experimental Usage,False,0.33,Low,,,,MYC,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MYC (Catalogue # 18583) | Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",Antibody target not in NF pathway/tumor biology gene list: MYC
phosphorylated ERK Thr202/Tyr204,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated ERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated ERK Thr202/Tyr204
phosphorylated Akt Ser473,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated Akt Ser473,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated Akt Ser473
phosphorylated S6 Ser235/236,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated S6 Ser235/236,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated S6 Ser235/236
γH2AX Ser139,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,γH2AX Ser139,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Coverslips were permeabilized and probed with anti-γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody",Antibody target not in NF pathway/tumor biology gene list: γH2AX Ser139
HIF1α,antibodies,PMID:33934112 | PMID:35393510 | PMID:33658640 | PMID:24824755,10.1038/s41419-021-03716-6 | 10.1038/s41418-022-00991-4 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit polyclonal anti-HIF1α was from Novus Biologicals (Cat. #NB100-449) | rabbit polyclonal anti-HIF1α was from GeneTex (Cat. #GTX131826) | IHC was performed using a primary rabbit polyclonal anti HIF1α antibody (Novus Biologicals, Centennials, CO, USA) | HIF1-α (rabbit, GTX127309, GeneTex, Irvine, CA, USA) | HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: HIF1α
BNIP3,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,BNIP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BNIP3 (Sigma, St. Louis, MO)",Antibody target not in NF pathway/tumor biology gene list: BNIP3
BECLIN1,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,0.33,Low,,,,BECLIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: BECLIN1
LC3,antibodies,PMID:38203448 | PMID:24824755,10.3390/ijms25010277 | 10.1371/journal.pone.0096733,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,False,0.33,Low,,,,LC3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA) | LC3 (Abgent, San Diego, CA)",Antibody target not in NF pathway/tumor biology gene list: LC3
p53,antibodies,PMID:32699356 | PMID:32948135 | PMID:32461556 | PMID:35945463 | PMID:30274821 | PMID:30055648 | PMID:24371224,10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1038/s41467-020-16432-0 | 10.1007/s00401-022-02478-5 | 10.1016/j.ebiom.2018.09.042 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-13-2062,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.95,Experimental Usage,False,0.67,Low,,,,p53,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems) | tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO) | probed with antibodies directed against p53 (sc-6243, 1:250, Santa Cruz Biotechnology) | p53 (Biocare, clone DO-7, 1:100 dilution, ER2 antigen retrieval) | p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling) | anti-p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713) | and p53 (1:500, NCL-p53-505, Novocastra) were used",Antibody target not in NF pathway/tumor biology gene list: p53
Olig2,antibodies,PMID:32699356 | PMID:18451155 | PMID:29715273 | PMID:35945463 | PMID:20554030 | PMID:20551058,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1371/journal.pone.0196726 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.95,Experimental Usage,False,0.67,Low,,,,Olig2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore) | BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz) | Guinea pig anti-Olig2 (1:10000, a kind gift of home-made antibody from Dr. B. Novitch) | anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany) | OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution, ER1 antigen retrieval) | The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles | Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute)",Antibody target not in NF pathway/tumor biology gene list: Olig2
p-S6,antibodies,PMID:32699356 | PMID:24509877 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1038/onc.2013.506 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling) | Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus) | p-S6 (1:1000, rabbit, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p-S6
BrdU,antibodies,PMID:32699356 | PMID:36322658 | PMID:29438698 | PMID:18636037 | PMID:18242513 | PMID:32396062 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1126/sciadv.abo5442 | 10.1016/j.ccell.2018.01.005 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.ccr.2008.01.003 | 10.7554/eLife.55137 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.33,Low,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rat anti-BrdU (ab6326, 1:500, Abcam) | BrdU (rat; Abcam, ab6326), VEGFA (rabbit; ABclonal, A0280) | BrdU (Rat; Abcam, ab6326), α-SMA (Mouse; Sigma, clone 1A4, A2547) | mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO) | cells were stained for BrdU using a flow-cytometry kit (BD Pharmingen; cat#559619) | Antibody anti-BrdU, rat monoclonal Thermo Fisher Cat. # MA 182088 RRID: AB_927214 1/500 dilution | Antibody anti-BrdU, mouse monoclonal Thermo Fisher Cat. # B35128 RRID: AB_2536432 Clone MoBu-1 | BrdU (1:1000, rat, Abcam, Cambridge, MA)",Generic reporter/tag/housekeeping antibody: brdu
Cytokeratin-8,antibodies,PMID:32461556 | PMID:24371224,10.1038/s41467-020-16432-0 | 10.1158/0008-5472.CAN-13-2062,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,Cytokeratin-8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cytokeratin-8 Santa Cruz, sc-101459 1:50 Overnight, RT Citrate buffer, pH 6.0 | Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma)",Antibody target not in NF pathway/tumor biology gene list: Cytokeratin-8
ABCC1,antibodies,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,Experimental Usage,False,0.33,Low,,,,ABCC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,Antibody target not in NF pathway/tumor biology gene list: ABCC1
mCherry,antibodies,PMID:34415582 | PMID:20551058,10.1002/glia.24075 | 10.1158/0008-5472.CAN-09-3769,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.95,Experimental Usage,False,0.67,Low,,,,mCherry,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse anti-mCherry, Abcam, Cat. # ab125096 (1:500) | Clontech (Dsred (mCherry))",Generic reporter/tag/housekeeping antibody: mcherry
NHE1,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,False,1.00,Medium,,,,NHE1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",Antibody target not in NF pathway/tumor biology gene list: NHE1
ERBB3 Y1197,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,ERBB3 Y1197,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: ERBB3 Y1197
ERBB3,antibodies,PMID:33273014 | PMID:20195187,10.1074/jbc.RA120.014960 | 10.1097/MAO.0b013e3181d2777f,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,ERBB3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling | polyclonal anti-ErbB3 (1:250; Santa Cruz)",Antibody target not in NF pathway/tumor biology gene list: ERBB3
EPHA2 S897,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,EPHA2 S897,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: EPHA2 S897
NDRG1 T346,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,NDRG1 T346,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: NDRG1 T346
Akt S473,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt S473,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473, Akt T308... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt S473
Akt T308,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,Akt T308,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt S473, Akt T308, Akt... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Akt T308
p70S6K T389,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,p70S6K T389,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt, p70S6K T389, p70S6K... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: p70S6K T389
p70S6K,antibodies,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,p70S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K T389, p70S6K, ribosomal S6 S240/244... were from Cell Signaling | p70 S6K, phospho-Akt (S473), Akt",Antibody target not in NF pathway/tumor biology gene list: p70S6K
ribosomal S6 S240/244,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,ribosomal S6 S240/244,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K, ribosomal S6 S240/244, S6... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: ribosomal S6 S240/244
S6,antibodies,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... ribosomal S6 S240/244, S6, IGF1R Y1135/36/IR Y1150/51... were from Cell Signaling | Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",Antibody target not in NF pathway/tumor biology gene list: S6
IGF1R Y1135/36/IR Y1150/51,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,IGF1R Y1135/36/IR Y1150/51,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... S6, IGF1R Y1135/36/IR Y1150/51, IGF1R... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: IGF1R Y1135/36/IR Y1150/51
IGF1R,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,IGF1R,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R Y1135/36/IR Y1150/51, IGF1R, FOXO1/3a T24/T32... were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: IGF1R
FOXO1/3a T24/T32,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXO1/3a T24/T32,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R, FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: FOXO1/3a T24/T32
FOXO3,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: FOXO3
EPHA2,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,EPHA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included EPHA2 (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: EPHA2
secreted form of NRG1,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.33,Low,,,,secreted form of NRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... secreted form of NRG1 (R&D Systems),Antibody target not in NF pathway/tumor biology gene list: secreted form of NRG1
NDRG1,antibodies,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,NDRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other antibodies included... NDRG1 (Abcam) | NDRG1 (Abcam; Cambridge, MA)",Antibody target not in NF pathway/tumor biology gene list: NDRG1
STING,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,STING,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"STING (13647S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: STING
TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TBK1 (3504T, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: TBK1
p-TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-TBK1 (s172) (5483T, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-TBK1
IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IRF3 (MA5-32348, Invitrogen, Thermo Fisher Scientific)",Antibody target not in NF pathway/tumor biology gene list: IRF3
p-IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-IRF3 (4947S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-IRF3
NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF-κB (ab16502, Abcam)",Antibody target not in NF pathway/tumor biology gene list: NF-κB
p-NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,p-NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p–NF-κB (3033S, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: p-NF-κB
PD-L1,antibodies,PMID:38502231 | PMID:40025578 | PMID:39321200 | PMID:37410426,10.1172/JCI176748 | 10.1186/s40478-025-01965-6 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.33,Low,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PD-L1 (ab213480, Abcam, 66248-1-Ig, Proteintech) | 100 μg mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell) | rabbit anti-human PDL1 (Genetex, GTX104763) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3, human leukocyte antigen (HLA)-class I, and PD-L1 | bi-weekly intraperitoneal injections of 10 mg/kg anti-PDL1 antibody (BioXCell BE0101)",Antibody target not in NF pathway/tumor biology gene list: PD-L1
CTLA-4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.67,Low,,,,CTLA-4,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CTLA-4 (BE0164, Bio X Cell) | 300 μg mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: CTLA-4
CD20,antibodies,PMID:38502231 | PMID:30531922,10.1172/JCI176748 | 10.1038/s41591-018-0263-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,CD20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD20 (BS-0080R, Bioss) | CD20 (Leica, NCL-L-CD20-L26, 1:200)",Antibody target not in NF pathway/tumor biology gene list: CD20
CD8α,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,False,0.33,Low,,,,CD8α,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD8α (PA5-81344),Antibody target not in NF pathway/tumor biology gene list: CD8α
iNOS,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,iNOS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"iNOS (ab15323, Abcam)",Antibody target not in NF pathway/tumor biology gene list: iNOS
mannose receptor,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,mannose receptor,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mannose receptor (ab64693, Abcam)",Antibody target not in NF pathway/tumor biology gene list: mannose receptor
p-H3,antibodies,PMID:38502231 | PMID:39415595,10.1172/JCI176748 | 10.1242/dmm.050862,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,0.33,Low,,,,p-H3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-H3 (ser10) (9701s, Cell Signaling Technology) | The embryos were incubated in anti-pH3 antibody overnight at 4°C",Antibody target not in NF pathway/tumor biology gene list: p-H3
cleaved PARP,antibodies,PMID:38502231 | PMID:38714355 | PMID:33658640,10.1172/JCI176748 | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41416-021-01270-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.33,Low,,,,cleaved PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved PARP (9488S, Cell Signaling Technology) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10)",Antibody target not in NF pathway/tumor biology gene list: cleaved PARP
PD-1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.33,Low,,,,PD-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti–PD-1 (ab214421, Abcam; 66220-1-Ig, Proteintech) antibodies | 250 μg mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)",Antibody target not in NF pathway/tumor biology gene list: PD-1
βIII-tubulin,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,βIII-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The mouse anti-βIII-tubulin antibody Tuj1 was obtained from R&D system,Antibody target not in NF pathway/tumor biology gene list: βIII-tubulin
NGFR,antibodies,PMID:41022755 | PMID:38744290,10.1038/s41467-025-63619-4 | 10.1016/j.crmeth.2024.100772,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.95,Experimental Usage,False,1.00,Medium,,,,NGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System | NGFR Biocare Medical CAT#ACI369A,Antibody target not in NF pathway/tumor biology gene list: NGFR
Human Nuclear Antigen,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,Human Nuclear Antigen,Rabbit,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher,Generic reporter/tag/housekeeping antibody: human nuclear antigen
phospho-ERK,antibodies,PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:34011935 | PMID:38714355 | PMID:39472976 | PMID:18413802,10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-07-0518,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-ERK,Mouse,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐phospho‐ERK (mouse, Sigma M8159, 1 : 2500) | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10), anti-phospho-ERK (mouse, Sigma M8159, 1:2500) | phospho-ERK (#D13.14.4E) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250) | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: phospho-ERK
PARP,antibodies,PMID:39129390 | PMID:33658640 | PMID:25043298,10.1002/1878-0261.13704 | 10.1038/s41416-021-01270-8 | 10.1038/onc.2014.185,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,PARP,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐PARP (rabbit, Cell Signaling 952, 1 : 1000) | total PARP (rabbit, #9542) (Cell Signaling, Danvers, MA, USA) | Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: PARP
LC3B,antibodies,PMID:39129390 | PMID:38203448,10.1002/1878-0261.13704 | 10.3390/ijms25010277,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.67,Low,,,,LC3B,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐LC3B (rabbit, Cell Signaling 2775, 1 : 1000; CST Danvers, MA USA) | anti-LC3B (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: LC3B
p44/42 MAPK (ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p44/42 MAPK (ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: p44/42 MAPK (ERK1/2)
p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2)
phosphatidylinositol 3-kinase (PI3K),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,0.67,Low,,,,phosphatidylinositol 3-kinase (PI3K),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",Antibody target not in NF pathway/tumor biology gene list: phosphatidylinositol 3-kinase (PI3K)
ATRX,antibodies,PMID:31462295 | PMID:30531922 | PMID:35945463,10.1186/s40478-019-0792-5 | 10.1038/s41591-018-0263-8 | 10.1007/s00401-022-02478-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,ATRX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using an ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich) | Primary ATRX antibody was from Sigma-Aldrich (HPA001906) and was used at 1:200 dilution | ATRX (Sigma, polyclonal, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: ATRX
GZMB,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,False,0.33,Low,,,,GZMB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GZMB (Leica, PA0291, ready to use)",Antibody target not in NF pathway/tumor biology gene list: GZMB
CD68,antibodies,PMID:30531922 | PMID:38216587,10.1038/s41591-018-0263-8 | 10.1038/s41467-023-40408-5,The molecular landscape of glioma in patients with Neurofibromatosis 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,CD68,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD68 (Sigma, HPA048982, 1:2,000) | or CD68 (M0814, Agilent Technologies; labeling validated using human B-cell lymphoma) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: CD68
"indoleamine 2,3-dioxygenase",antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,False,1.00,Medium,,,,"indoleamine 2,3-dioxygenase",Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)","Antibody target not in NF pathway/tumor biology gene list: indoleamine 2,3-dioxygenase"
AHR,antibodies,PMID:38931352 | PMID:34011935,10.3390/ph17060685 | 10.1038/s41419-021-03802-9,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.95,Experimental Usage,False,1.00,Medium,,,,AHR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA) | Antibody for Aryl hydrocarbon receptor (AHR, #H-211)",Antibody target not in NF pathway/tumor biology gene list: AHR
TDO2,antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,False,1.00,Medium,,,,TDO2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",Antibody target not in NF pathway/tumor biology gene list: TDO2
HDAC1,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,HDAC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: HDAC1
PDLIM2,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,0.33,Low,,,,PDLIM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology | PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore",Antibody target not in NF pathway/tumor biology gene list: PDLIM2
EMA,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,False,0.33,Low,,,,EMA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",Antibody target not in NF pathway/tumor biology gene list: EMA
vimentin,antibodies,PMID:30055648 | PMID:33356508 | PMID:39996452,10.1186/s13104-018-3630-0 | 10.1177/0963689720964383 | 10.1111/cns.70287,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,vimentin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4) | Vimentin-antigen presenting cell (APC) (expressed by C6 cells) | examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",Antibody target not in NF pathway/tumor biology gene list: vimentin
CD31,antibodies,PMID:33442015 | PMID:29847659 | PMID:41444363 | PMID:34010628 | PMID:18483311 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1167/iovs.17-22588 | 10.1038/s41598-025-32031-9 | 10.1016/j.stem.2021.04.029 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.95,Experimental Usage,False,0.33,Low,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam) | anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA) | Anti-CD31 (Abcam, ab7388) for vasculature | endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410) | Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature | CD31 (3528S, 1:100, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: CD31
AXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,AXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam) | pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: AXL
pAXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pAXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: pAXL
pGSK-3β,antibodies,PMID:33442015 | PMID:26904939,10.1038/s41591-020-01193-6 | 10.1016/j.celrep.2016.01.074,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.95,Experimental Usage,False,0.33,Low,,,,pGSK-3β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: pGSK-3β
pMEK1/2,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,False,0.33,Low,,,,pMEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pMEK1/2
CalbindinD-28K,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,CalbindinD-28K,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland | mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955), Munich, Germany",Antibody target not in NF pathway/tumor biology gene list: CalbindinD-28K
MBP,antibodies,PMID:29715273 | PMID:24509877 | PMID:40684195,10.1371/journal.pone.0196726 | 10.1038/onc.2013.506 | 10.1186/s40478-025-02075-z,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,MBP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany) | Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | rat anti-MBP (1:200; Chemicon Millipore #MAB386)",Antibody target not in NF pathway/tumor biology gene list: MBP
phospho-Histone H3,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Histone H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)",Antibody target not in NF pathway/tumor biology gene list: phospho-Histone H3
cyclophilin B,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.33,Low,,,,cyclophilin B,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",Antibody target not in NF pathway/tumor biology gene list: cyclophilin B
MAF,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,MAF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: MAF
DEPTOR,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,0.33,Low,,,,DEPTOR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",Antibody target not in NF pathway/tumor biology gene list: DEPTOR
S100β,antibodies,PMID:24509877 | PMID:21551250 | PMID:34040258 | PMID:40025578 | PMID:26904939 | PMID:40684195 | PMID:20049725,10.1038/onc.2013.506 | 10.1158/0008-5472.CAN-10-4577 | 10.1038/s41586-021-03580-6 | 10.1186/s40478-025-01965-6 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1002/emmm.200900027,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,0.33,Low,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | S100β (rabbit, 1:5000, DAKO) | rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1) | S100β- Alexa Fluor 647 (Abcam, ab196175) | incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA | mouse anti-S100β (1:300; Abcam #ab218516) | We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody",Antibody target not in NF pathway/tumor biology gene list: S100β
BLBP,antibodies,PMID:24509877 | PMID:25535838,10.1038/onc.2013.506 | 10.7554/eLife.05151,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,BLBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony)",Antibody target not in NF pathway/tumor biology gene list: BLBP
CD34,antibodies,PMID:29941005 | PMID:30055648 | PMID:38744290 | PMID:33767727,10.1186/s13023-018-0843-1 | 10.1186/s13104-018-3630-0 | 10.1016/j.crmeth.2024.100772 | 10.3389/fgene.2021.603195,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems)... | anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10) to demonstrate vessel and stem cell formation | CD34 Santa Cruz Biotechnology CAT#SC-74499; RRID: AB_1120394 | FITC Anti-CD34 antibody [4H11[APG]] (ab18227) | strong and diffuse CD34 positivity in the tumor cell cytoplasm",Antibody target not in NF pathway/tumor biology gene list: CD34
RHAMM,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,RHAMM,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies were sourced as follows: RHAMM (Epitomics),Antibody target not in NF pathway/tumor biology gene list: RHAMM
TPX2,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,TPX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TPX2 (Novus),Antibody target not in NF pathway/tumor biology gene list: TPX2
nestin,antibodies,PMID:18451155 | PMID:36322658 | PMID:40684195 | PMID:23328114 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1126/sciadv.abo5442 | 10.1186/s40478-025-02075-z | 10.18632/oncotarget.793 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,nestin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling) | Nestin (mouse; Millipore, MAB353), EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113) | rabbit anti-nestin (1:100; Abcam # ab221660) | nestin (Covance) | Anti-Nestin antibody primary IF CST (Danvers, USA)",Antibody target not in NF pathway/tumor biology gene list: nestin
AURKA,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,AURKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",Antibody target not in NF pathway/tumor biology gene list: AURKA
phospho-AURKA (Thr288),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-AURKA (Thr288),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho (p)-AURKA (Thr288),Antibody target not in NF pathway/tumor biology gene list: phospho-AURKA (Thr288)
p-histone H3 (Ser10),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,0.33,Low,,,,p-histone H3 (Ser10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-histone H3 (Ser10),Antibody target not in NF pathway/tumor biology gene list: p-histone H3 (Ser10)
p-RHAMM (Thr703),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,False,0.67,Low,,,,p-RHAMM (Thr703),Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The p-RHAMM (Thr703) polyclonal antibody is characterized in [11],Antibody target not in NF pathway/tumor biology gene list: p-RHAMM (Thr703)
PDGFRβ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,PDGFRβ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to PDGFRβ (rabbit; Abcam, ab32570), α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547)",Antibody target not in NF pathway/tumor biology gene list: PDGFRβ
α-SMA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,α-SMA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547), IBA1 (rabbit; Wako Chemicals, 019-19741)",Antibody target not in NF pathway/tumor biology gene list: α-SMA
GLUT1,antibodies,PMID:36322658 | PMID:33934112 | PMID:38203448,10.1126/sciadv.abo5442 | 10.1038/s41419-021-03716-6 | 10.3390/ijms25010277,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.67,Low,,,,GLUT1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GLUT1 (rabbit; Abcam, ab652), cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661) | rabbit polyclonal anti-glucose transporter GLUT1 was from Abcam (Cat. #ab652) | anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies",Antibody target not in NF pathway/tumor biology gene list: GLUT1
VEGFA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,VEGFA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"VEGFA (rabbit; ABclonal, A0280), ALDH1A1 (rabbit; Proteintech, 15910-1-AP)",Antibody target not in NF pathway/tumor biology gene list: VEGFA
ALDH1A1,antibodies,PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.67,Low,,,,ALDH1A1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (rabbit; Proteintech, 15910-1-AP), ZEB1 (rabbit; ABclonal, A5600) | ALDH1A1 (1:200; ab52492; Abcam)",Antibody target not in NF pathway/tumor biology gene list: ALDH1A1
ZEB1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,ZEB1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ZEB1 (rabbit; ABclonal, A5600), IGFBP2 (rabbit; Cell Signaling Technology, #3922)",Antibody target not in NF pathway/tumor biology gene list: ZEB1
IGFBP2,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,IGFBP2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IGFBP2 (rabbit; Cell Signaling Technology, #3922), Nestin (mouse; Millipore, MAB353)",Antibody target not in NF pathway/tumor biology gene list: IGFBP2
EYA4,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,EYA4,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113), SOX2 (goat; Santa Cruz Biotechnology, sc-17320)",Antibody target not in NF pathway/tumor biology gene list: EYA4
SOX2,antibodies,PMID:36730269 | PMID:36322658 | PMID:38744290 | PMID:36241865 | PMID:24371224,10.1371/journal.pone.0277305 | 10.1126/sciadv.abo5442 | 10.1016/j.crmeth.2024.100772 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-13-2062,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.95,Experimental Usage,False,0.33,Low,,,,SOX2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX2 (Catalogue # MAB2018) from R&D systems | SOX2 (goat; Santa Cruz Biotechnology, sc-17320), and YAP/TAZ (rabbit; Cell Signaling Technology, #8418) | SOX2 Biocare Medical CAT#ACI3109A | Anti-SOX2 antibody primary IF CST | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: SOX2
YAP/TAZ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,YAP/TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP/TAZ (rabbit; Cell Signaling Technology, #8418). Secondary antibodies conjugated to Alexa Fluor 488",Antibody target not in NF pathway/tumor biology gene list: YAP/TAZ
GAP43,antibodies,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,False,0.67,Low,,,,GAP43,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAP43 (rabbit, 1:1000, Abcam)",Antibody target not in NF pathway/tumor biology gene list: GAP43
p75 NGFR,antibodies,PMID:37520682 | PMID:28256556,10.1016/j.omtn.2023.06.018 | 10.1038/srep43315,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.33,Low,,,,p75 NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection | anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)",Antibody target not in NF pathway/tumor biology gene list: p75 NGFR
PDGFRα,antibodies,PMID:34040258 | PMID:40684195,10.1038/s41586-021-03580-6 | 10.1186/s40478-025-02075-z,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,PDGFRα,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897) | goat anti-PDGFRα (1:100; R&D system #AF1062)",Antibody target not in NF pathway/tumor biology gene list: PDGFRα
NLGN3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,NLGN3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108",Antibody target not in NF pathway/tumor biology gene list: NLGN3
ADAM10,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,ADAM10,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5",Antibody target not in NF pathway/tumor biology gene list: ADAM10
caspase-3,antibodies,PMID:34040258 | PMID:30274821 | PMID:35511749 | PMID:38216572 | PMID:18367665,10.1038/s41586-021-03580-6 | 10.1016/j.ebiom.2018.09.042 | 10.1158/1535-7163.MCT-21-0947 | 10.1038/s41467-024-44755-9 | 10.1124/jpet.107.135830,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,0.67,Low,,,,caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19 | caspase-3 (# 9662, Cell Signaling) | Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology | Caspase-3 (Cell Signaling Technologies, #9662, 1:1000 dilution) | Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: caspase-3
tau 1,antibodies,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,False,0.33,Low,,,,tau 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)",Antibody target not in NF pathway/tumor biology gene list: tau 1
PTCH1,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.33,Low,,,,PTCH1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PTCH1(1:500,Cat#MAB41051, R&D systems)",Antibody target not in NF pathway/tumor biology gene list: PTCH1
β-catenin,antibodies,PMID:23535903 | PMID:26904939,10.1158/2159-8290.CD-13-0081 | 10.1016/j.celrep.2016.01.074,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.",,0.9,Experimental Usage,False,0.33,Low,,,,β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (β-catenin, 1:100, Cell Signaling) | The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling) | Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200) | anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: β-catenin
FBXW11/bTrCP2,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,FBXW11/bTrCP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)",Antibody target not in NF pathway/tumor biology gene list: FBXW11/bTrCP2
pERK Thr202/Tyr204,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.33,Low,,,,pERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: pERK Thr202/Tyr204
synaptophysin,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,synaptophysin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"synaptophysin (Cell Marque, polyclonal, 1:100 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: synaptophysin
p16,antibodies,PMID:35945463 | PMID:34065204 | PMID:30055648,10.1007/s00401-022-02478-5 | 10.3390/ijms22105367 | 10.1186/s13104-018-3630-0,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,False,0.67,Low,,,,p16,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p16 (MTM Labs, clone E6H4, undiluted, ER1 antigen retrieval) | human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam | mouse p16 (sc-1207, 1:200) from Santa Cruz Biotechnology | anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9",Antibody target not in NF pathway/tumor biology gene list: p16
histone H3 K27M mutant protein,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,histone H3 K27M mutant protein,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 K27M mutant protein (RevMAb Biosciences, clone RM192, 1:600 dilution)",Antibody target not in NF pathway/tumor biology gene list: histone H3 K27M mutant protein
histone H3 lysine 27 trimethylation,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,histone H3 lysine 27 trimethylation,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 lysine 27 trimethylation (Cell Signaling, cat #9733, clone C36B11, 1:50 dilution, ER2 antigen retrieval)",Antibody target not in NF pathway/tumor biology gene list: histone H3 lysine 27 trimethylation
CD16/CD32,antibodies,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,0.33,Low,,,,CD16/CD32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min,Antibody target not in NF pathway/tumor biology gene list: CD16/CD32
CD24,antibodies,PMID:40217315 | PMID:24371224,10.1186/s13073-025-01462-4 | 10.1158/0008-5472.CAN-13-2062,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.95,Experimental Usage,False,0.67,Low,,,,CD24,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec) | 1 × 106 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences)",Antibody target not in NF pathway/tumor biology gene list: CD24
CD44,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.67,Low,,,,CD44,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec) and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)",Antibody target not in NF pathway/tumor biology gene list: CD44
HLA Class I ABC,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.33,Low,,,,HLA Class I ABC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I",Antibody target not in NF pathway/tumor biology gene list: HLA Class I ABC
MHC Class II,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,False,0.33,Low,,,,MHC Class II,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II",Antibody target not in NF pathway/tumor biology gene list: MHC Class II
Pericentrin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,Pericentrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",Antibody target not in NF pathway/tumor biology gene list: Pericentrin
γTubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,γTubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",Antibody target not in NF pathway/tumor biology gene list: γTubulin
Acetylated Tubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.33,Low,,,,Acetylated Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and Acetylated Tubulin to mark cilia (T6793, Sigma; labeling validated in vertebrate and invertebrate organisms)",Generic reporter/tag/housekeeping antibody: acetylated tubulin
CD13,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD13,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...incubated for 30 min in ice and in the dark with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)...",Antibody target not in NF pathway/tumor biology gene list: CD13
CD14,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD14,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK), CD14/PE (M5E2, BD Biosciences, CA, USA)...",Antibody target not in NF pathway/tumor biology gene list: CD14
CD105,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD105,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences)...",Antibody target not in NF pathway/tumor biology gene list: CD105
CD146,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD146,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences)...",Antibody target not in NF pathway/tumor biology gene list: CD146
CD271,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,False,1.00,Medium,,,,CD271,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls...",Antibody target not in NF pathway/tumor biology gene list: CD271
OCT3/4,antibodies,PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,OCT3/4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: OCT3/4
NANOG,antibodies,PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,NANOG,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",Antibody target not in NF pathway/tumor biology gene list: NANOG
MKK3,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,MKK3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674),Antibody target not in NF pathway/tumor biology gene list: MKK3
p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p38 (Cell Signaling #9219),Antibody target not in NF pathway/tumor biology gene list: p38
phospho-p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-p38 (Cell Signaling # 4511),Antibody target not in NF pathway/tumor biology gene list: phospho-p38
TAZ,antibodies,PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.67,Low,,,,TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to TAZ (Rabbit; Proteintech 23306-1), YAP (Rabbit; Cell Signaling Technology, #4912) | TAZ (1:100; sc-48805; Santa Cruz)",Antibody target not in NF pathway/tumor biology gene list: TAZ
YAP,antibodies,PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.67,Low,,,,YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP (Rabbit; Cell Signaling Technology, #4912), TAZ/YAP (Rabbit; Cell Signaling Technology, #8418) | YAP (1:100; #14074; CST)",Antibody target not in NF pathway/tumor biology gene list: YAP
TAZ/YAP,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TAZ/YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TAZ/YAP (Rabbit; Cell Signaling Technology, #8418), Sox10 (Goat, Santa Cruz Biotechnology, sc-17342",Antibody target not in NF pathway/tumor biology gene list: TAZ/YAP
TEAD1,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,TEAD1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TEAD1 (Mouse, Santa Cruz Biotechnology sc-393976), neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67) | The antibodies used were as follows: TEAD1 (Mouse, BD Biosciences, 610922), H3K4me1 (Rabbit, Abcam, 8895)",Antibody target not in NF pathway/tumor biology gene list: TEAD1
Ubiquitin,antibodies,PMID:36730269 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.95,Experimental Usage,False,0.33,Low,,,,Ubiquitin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ubiquitin (Catalogue # 4289) | HA, HSP70, and Ubiquitin (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: Ubiquitin
pCHEK1 S296,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pCHEK1 S296,,,,,,,,,,,,,,,,,,,,,,,,,,,,pCHEK1 S296 (Catalogue # 90178),Antibody target not in NF pathway/tumor biology gene list: pCHEK1 S296
BMI1,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,BMI1,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMI1 (Catalogue # 5856),Antibody target not in NF pathway/tumor biology gene list: BMI1
H3K27Ac,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,H3K27Ac,,,,,,,,,,,,,,,,,,,,,,,,,,,,H3K27Ac (Catalogue # 8173),Antibody target not in NF pathway/tumor biology gene list: H3K27Ac
H3,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,total H3 (Catalogue # 14269),Antibody target not in NF pathway/tumor biology gene list: H3
CDK9,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,CDK9,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDK9 (Catalogue # 2316),Antibody target not in NF pathway/tumor biology gene list: CDK9
CPNase,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,CPNase,,,,,,,,,,,,,,,,,,,,,,,,,,,,CPNase (Catalogue # 5664),Antibody target not in NF pathway/tumor biology gene list: CPNase
MAG,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,MAG,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAG (Catalogue # 9043),Antibody target not in NF pathway/tumor biology gene list: MAG
pS2 RNApol II,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,False,0.33,Low,,,,pS2 RNApol II,,,,,,,,,,,,,,,,,,,,,,,,,,,,pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore,Antibody target not in NF pathway/tumor biology gene list: pS2 RNApol II
EGFR,antibodies,PMID:20195187 | PMID:28166733 | PMID:25043298,10.1097/MAO.0b013e3181d2777f | 10.1186/s12864-017-3519-7 | 10.1038/onc.2014.185,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFR,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA) | anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT) | Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",Antibody target not in NF pathway/tumor biology gene list: EGFR
ErbB2,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,ErbB2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",Antibody target not in NF pathway/tumor biology gene list: ErbB2
actin,antibodies,PMID:20195187 | PMID:30055648 | PMID:36420221 | PMID:33658640,10.1097/MAO.0b013e3181d2777f | 10.1186/s13104-018-3630-0 | 10.1016/j.omtn.2022.10.026 | 10.1038/s41416-021-01270-8,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.67,Low,,,,actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"monoclonal anti-actin (BD Biosciences, San Jose, CA) | anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4). Staining was visualized using the ultraView™ Universal Alkaline Phosphatase Red Detection Kit | An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes) | Actin (mouse, ACTN05(C4), NeoMarkers) at 1:1000 dilution",Generic reporter/tag/housekeeping antibody: actin
MPM-2,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,MPM-2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY)",Antibody target not in NF pathway/tumor biology gene list: MPM-2
cyclin D1,antibodies,PMID:32948135 | PMID:30274821 | PMID:33032988 | PMID:18413802,10.1186/s12885-020-07397-w | 10.1016/j.ebiom.2018.09.042 | 10.1158/0008-5472.CAN-20-1365 | 10.1158/1535-7163.MCT-07-0518,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.95,Experimental Usage,False,1.00,Medium,,,,cyclin D1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO) | cyclinD1 (# C7464, Sigma-Aldrich) | Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: cyclin D1
B-Raf,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,B-Raf,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",Antibody target not in NF pathway/tumor biology gene list: B-Raf
phospho-MEK1/2,antibodies,PMID:34011935 | PMID:18413802,10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-07-0518,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,0.67,Low,,,,phospho-MEK1/2,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 (#41G9) | phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-MEK1/2
phospho-Rb,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-Rb,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-Rb
MDM2,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,0.33,Low,,,,MDM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: MDM2
CXCL12,antibodies,PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.67,Low,,,,CXCL12,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12 | purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12) | Antibodies were obtained from Peprotech (CXCL12),Antibody target not in NF pathway/tumor biology gene list: CXCL12
Endoglin,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.67,Low,,,,Endoglin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,R&D (Goat anti-Endoglin),Antibody target not in NF pathway/tumor biology gene list: Endoglin
p-PKA substrate,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-PKA substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",Antibody target not in NF pathway/tumor biology gene list: p-PKA substrate
pS473-AKT,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,pS473-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",Antibody target not in NF pathway/tumor biology gene list: pS473-AKT
CXCR4,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,False,0.33,Low,,,,CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Leinco (pan-CXCR4),Antibody target not in NF pathway/tumor biology gene list: CXCR4
CNPase,antibodies,PMID:18451155 | PMID:20554030 | PMID:23685747 | PMID:36241865 | PMID:20551058,10.1158/0008-5472.CAN-07-6867 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/ng.2641 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.95,Experimental Usage,False,0.33,Low,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Gfap (Dako), CNPase (Chemicon), or nestin | Sigma (mouse anti-CNPase) | Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz) | Anti-CNPase antibody primary IF and WB CST | Sigma (CNPase)",Antibody target not in NF pathway/tumor biology gene list: CNPase
phosphorylated CXCR4,antibodies,PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.33,Low,,,,phosphorylated CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab | Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described,Antibody target not in NF pathway/tumor biology gene list: phosphorylated CXCR4
phosphorylated PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: phosphorylated PKA
PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: PKA
phosphorylated CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,phosphorylated CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: phosphorylated CREB
CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology,Antibody target not in NF pathway/tumor biology gene list: CREB
P-glycoprotein,antibodies,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,False,0.33,Low,,,,P-glycoprotein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",Antibody target not in NF pathway/tumor biology gene list: P-glycoprotein
HSP70,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,HSP70,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: HSP70
GST,antibodies,PMID:21072183 | PMID:36689660,10.1371/journal.pone.0013791 | 10.1073/pnas.2208960120,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,False,0.33,Low,,,,GST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... GST (Santa Cruz Biotechnology) | GST and Vinculin (Bethyl Laboratories),Generic reporter/tag/housekeeping antibody: gst
RASA1,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,0.33,Low,,,,RASA1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,RASA1 (Santa Cruz Biotechnology),Antibody target not in NF pathway/tumor biology gene list: RASA1
RABL6A,antibodies,PMID:34065204 | PMID:37410426,10.3390/ijms22105367 | 10.1158/1078-0432.CCR-23-0749,"RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.67,Low,,,,RABL6A,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,RABL6A antibodies (monoclonal and polyclonal) were produced in the Quelle laboratory | Immunostaining for SIAH (24E6H3 mouse monoclonal antibody) and RABL6A was conducted,Antibody target not in NF pathway/tumor biology gene list: RABL6A
FOXR2,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,0.33,Low,,,,FOXR2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed",Antibody target not in NF pathway/tumor biology gene list: FOXR2
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,0.33,Low,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",Antibody target not in NF pathway/tumor biology gene list: Nuclear Pore Complex Proteins
HER1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,HER1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER1 (Abcam, ab52894) | HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",Antibody target not in NF pathway/tumor biology gene list: HER1
HER2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,HER2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",Antibody target not in NF pathway/tumor biology gene list: HER2
VEGFR2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,VEGFR2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human VEGFR2 (CST, 9698S)",Antibody target not in NF pathway/tumor biology gene list: VEGFR2
B7H3,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,B7H3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human B7H3 (CST, #14058)",Antibody target not in NF pathway/tumor biology gene list: B7H3
CD171,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,CD171,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human CD171 (Abcam, ab208155)",Antibody target not in NF pathway/tumor biology gene list: CD171
EGFRvIII,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,EGFRvIII,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",Antibody target not in NF pathway/tumor biology gene list: EGFRvIII
TGFβ1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,0.67,Low,,,,TGFβ1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human TGFβ1 (Abcam, ab215715)",Antibody target not in NF pathway/tumor biology gene list: TGFβ1
CD8a,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CD8a,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206)",Antibody target not in NF pathway/tumor biology gene list: CD8a
CD45RO,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CD45RO,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242)",Antibody target not in NF pathway/tumor biology gene list: CD45RO
CCR7,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.33,Low,,,,CCR7,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",Antibody target not in NF pathway/tumor biology gene list: CCR7
Mek1/2,antibodies,PMID:21072183 | PMID:34011935,10.1371/journal.pone.0013791 | 10.1038/s41419-021-03802-9,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.33,Low,,,,Mek1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology) | Antibodies used in western blotting targeting...MEK1/2,Antibody target not in NF pathway/tumor biology gene list: Mek1/2
MMP1,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,MMP1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,MMP1 (#E9S9N),Antibody target not in NF pathway/tumor biology gene list: MMP1
collagen I,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,0.67,Low,,,,collagen I,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,collagen I (#EPR7785),Antibody target not in NF pathway/tumor biology gene list: collagen I
S100 protein,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,False,0.33,Low,,,,S100 protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-S100 protein antibody (Nichirei Biosciences Inc.),Antibody target not in NF pathway/tumor biology gene list: S100 protein
β3-tubulin,antibodies,PMID:18451155 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.95,Experimental Usage,False,0.33,Low,,,,β3-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin | Anti-β3-Tubulin antibody primary IF and WB CST",Antibody target not in NF pathway/tumor biology gene list: β3-tubulin
S100A10,antibodies,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,False,0.67,Low,,,,S100A10,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems),Antibody target not in NF pathway/tumor biology gene list: S100A10
Cdk1,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Cdk1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Cdk1
phospho-Cdk1 Tyr15,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-Cdk1 Tyr15,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-Cdk1 Tyr15
Acetyl-Histone H3 Lys18,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,Acetyl-Histone H3 Lys18,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: Acetyl-Histone H3 Lys18
SAPK/JNK,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,SAPK/JNK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: SAPK/JNK
phospho-SAPK/JNK Thr183/Tyr185,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-SAPK/JNK Thr183/Tyr185,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-SAPK/JNK Thr183/Tyr185
p70S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,p70S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: p70S6 Kinase
phospho-p70 Thr389 S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-p70 Thr389 S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-p70 Thr389 S6 Kinase
phospho-S6 (Ser240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-S6 (Ser240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)",Antibody target not in NF pathway/tumor biology gene list: phospho-S6 (Ser240/244)
phospho-S6 (S240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-S6 (S240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",Antibody target not in NF pathway/tumor biology gene list: phospho-S6 (S240/244)
phospho-p70 S6K (T389),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-p70 S6K (T389),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-p70 S6K (T389), p70 S6K, phospho-Akt (S473)",Antibody target not in NF pathway/tumor biology gene list: phospho-p70 S6K (T389)
phospho-Akt (S473),antibodies,PMID:26219339 | PMID:18483311,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-07-2335,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-Akt (S473),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346) | Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-Akt (S473)
phospho-NDRG1 (T346),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-NDRG1 (T346),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-NDRG1 (T346), SGK1, phospho-PAK1 (S144)",Antibody target not in NF pathway/tumor biology gene list: phospho-NDRG1 (T346)
SGK1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,SGK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SGK1, phospho-PAK1 (S144), PAK1",Antibody target not in NF pathway/tumor biology gene list: SGK1
phospho-PAK1 (S144),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-PAK1 (S144),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-PAK1 (S144), PAK1, and 4EBP1",Antibody target not in NF pathway/tumor biology gene list: phospho-PAK1 (S144)
PAK1,antibodies,PMID:26219339 | PMID:21072183,10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,PAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology | The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology)",Antibody target not in NF pathway/tumor biology gene list: PAK1
4EBP1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,4EBP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: 4EBP1
Rac1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.33,Low,,,,Rac1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Rac1 (BD Biosciences; San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: Rac1
Rheb,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,0.67,Low,,,,Rheb,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)",Antibody target not in NF pathway/tumor biology gene list: Rheb
tubulin,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,,,,tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)",Generic reporter/tag/housekeeping antibody: tubulin
Pak2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.33,Low,,,,Pak2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: Pak2
phospho-MEK1 (Ser298),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-MEK1 (Ser298),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-MEK1 (Ser298)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-MEK1 (Ser298)
phospho-Erk1/2 (Thr202/Tyr204),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Erk1/2 (Thr202/Tyr204),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Erk1/2 (Thr202/Tyr204)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-Erk1/2 (Thr202/Tyr204)
phospho-Akt (Thr308),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Akt (Thr308),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Akt (Thr308)... (Cell Signaling Technology),Antibody target not in NF pathway/tumor biology gene list: phospho-Akt (Thr308)
phospho-Pak1–3 (Ser141),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,0.33,Low,,,,phospho-Pak1–3 (Ser141),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Pak1–3 (Ser141; Invitrogen),Antibody target not in NF pathway/tumor biology gene list: phospho-Pak1–3 (Ser141)
DUSP6,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,DUSP6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against DUSP6 (# ab76310) were from Abcam,Antibody target not in NF pathway/tumor biology gene list: DUSP6
panendothelial cell antigen,antibodies,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,False,0.33,Low,,,,panendothelial cell antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",Antibody target not in NF pathway/tumor biology gene list: panendothelial cell antigen
P-Stat3 (Y705),antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Stat3 (Y705),,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: P-Stat3 (Y705)
P-Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-Jak2
Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: Jak2
p-STAT3,antibodies,PMID:33658640 | PMID:26904939,10.1038/s41416-021-01270-8 | 10.1016/j.celrep.2016.01.074,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.95,Experimental Usage,False,1.00,Medium,,,,p-STAT3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-STAT3 (Y705) (rabbit monoclonal 1:25 dilution, Cell Signaling, D3A7) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: p-STAT3
Stat3,antibodies,PMID:26904939 | PMID:33658640,10.1016/j.celrep.2016.01.074 | 10.1038/s41416-021-01270-8,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.33,Low,,,,Stat3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA) | STAT3 (mouse, 124H6), Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10), total PARP (rabbit, #9542) (Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: Stat3
P-β-catenin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,P-β-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: P-β-catenin
GSK3β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,0.33,Low,,,,GSK3β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",Antibody target not in NF pathway/tumor biology gene list: GSK3β
CD16/32,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CD16/32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)",Antibody target not in NF pathway/tumor biology gene list: CD16/32
Ter119,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,False,0.33,Low,,,,Ter119,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 116208)",Antibody target not in NF pathway/tumor biology gene list: Ter119
p75,antibodies,PMID:18242513 | PMID:38175707,10.1016/j.ccr.2008.01.003 | 10.1172/jci.insight.168826,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,p75,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon) | incubated for 30 minutes on ice with unconjugated primary antibody p75 (1:1,000, Ab3125, Abcam)",Antibody target not in NF pathway/tumor biology gene list: p75
α4 integrin,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,0.33,Low,,,,α4 integrin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)",Antibody target not in NF pathway/tumor biology gene list: α4 integrin
phospho-histone-H3 (Ser 10),antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,False,0.33,Low,,,,phospho-histone-H3 (Ser 10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc.",Antibody target not in NF pathway/tumor biology gene list: phospho-histone-H3 (Ser 10)
"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,Experimental Usage,False,0.33,Low,,,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution","Antibody target not in NF pathway/tumor biology gene list: Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)"
phospho-MEK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho-MEK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-MEK
RAD51,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,RAD51,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: RAD51
BRCA2,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,0.33,Low,,,,BRCA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: BRCA2
MGMT,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,MGMT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,MGMT (sc-166528) was obtained from Santa Cruz Biotechnology,Antibody target not in NF pathway/tumor biology gene list: MGMT
yH2AX,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.33,Low,,,,yH2AX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",Antibody target not in NF pathway/tumor biology gene list: yH2AX
podoplanin,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,False,0.67,Low,,,,podoplanin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",Antibody target not in NF pathway/tumor biology gene list: podoplanin
F4/80,antibodies,PMID:40684195 | PMID:28256556,10.1186/s40478-025-02075-z | 10.1038/srep43315,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.67,Low,,,,F4/80,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-F4/80 (1:400; Abcam #ab6640) | anti-F4/80 bound to Cy5.5 on ice in a solution containing phosphate-buffered saline,Antibody target not in NF pathway/tumor biology gene list: F4/80
CSF1,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,False,0.67,Low,,,,CSF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium,Antibody target not in NF pathway/tumor biology gene list: CSF1
tomato,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,tomato,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-tomato (1:1000; Kerafast #EST203),Generic reporter/tag/housekeeping antibody: tomato
cKIT,antibodies,PMID:40684195 | PMID:38744290,10.1186/s40478-025-02075-z | 10.1016/j.crmeth.2024.100772,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,cKIT,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-cKIT (1:100; R&D system #AF1356) | APC Anti-c-Kit antibody [YB5.B8] (ab95678),Antibody target not in NF pathway/tumor biology gene list: cKIT
POSTN,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,POSTN,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-POSTN (1:400; BioTechne #AF2955),Antibody target not in NF pathway/tumor biology gene list: POSTN
TNC,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,TNC,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-TNC (1:100; Abcam #ab108930),Antibody target not in NF pathway/tumor biology gene list: TNC
PGP9.5,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,PGP9.5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-PGP9.5 (1:100; Abcam #ab108986),Antibody target not in NF pathway/tumor biology gene list: PGP9.5
Aqp1,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Aqp1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse A488-anti-Aqp1 (1:100; Santa Cruz Biotech #sc-25287),Antibody target not in NF pathway/tumor biology gene list: Aqp1
KIF11,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,KIF11,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated with anti-KIF11 antibody (Proteintech),Antibody target not in NF pathway/tumor biology gene list: KIF11
KIF15,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,KIF15,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-KIF15 antibody (Proteintech),Antibody target not in NF pathway/tumor biology gene list: KIF15
PGDS,antibodies,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,False,1.00,Medium,,,,PGDS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)",Antibody target not in NF pathway/tumor biology gene list: PGDS
phospho-S6K (T389),antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,phospho-S6K (T389),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",Antibody target not in NF pathway/tumor biology gene list: phospho-S6K (T389)
S6K1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,S6K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Total S6K1 antibody was used as previously described,Antibody target not in NF pathway/tumor biology gene list: S6K1
Mib1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,Mib1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)",Antibody target not in NF pathway/tumor biology gene list: Mib1
PDE4A,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,PDE4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Abcam (PDE4A & 58kD Golgi marker),Antibody target not in NF pathway/tumor biology gene list: PDE4A
LCA,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,LCA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pharmingen (LCA),Antibody target not in NF pathway/tumor biology gene list: LCA
phosphorylated protein kinase A substrate,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,False,0.33,Low,,,,phosphorylated protein kinase A substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Cell Signaling (phosphorylated protein kinase A (pPKA) substrate),Antibody target not in NF pathway/tumor biology gene list: phosphorylated protein kinase A substrate
MPZ,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,False,0.33,Low,,,,MPZ,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MPZ (1:100, Ab183868, Abcam), overnight at 4ºC",Antibody target not in NF pathway/tumor biology gene list: MPZ
Survivin,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,Survivin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Survivin (MA5–15077, 1:200, Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: Survivin
CENPF,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,False,0.33,Low,,,,CENPF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CENPF (PA5–84637, 1:200, Invitrogen) | CENPF (ab223847, 1:1000 dilution, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CENPF
CD56,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,CD56,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD56 Biocare Medical CAT#CM164A,Antibody target not in NF pathway/tumor biology gene list: CD56
CD117/c-kit,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,CD117/c-kit,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD117/c-kit Biocare Medical CAT#CME296AK; RRID: AB_10581782,Antibody target not in NF pathway/tumor biology gene list: CD117/c-kit
PanCytokeratin,antibodies,PMID:38744290 | PMID:24371224,10.1016/j.crmeth.2024.100772 | 10.1158/0008-5472.CAN-13-2062,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.67,Low,,,,PanCytokeratin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PanCytokeratin Biocare Medical CAT#CM011A; RRID: AB_2811020 | Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),Antibody target not in NF pathway/tumor biology gene list: PanCytokeratin
S100A11,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,False,0.67,Low,,,,S100A11,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Recombinant PE Anti-S100A11 antibody [EPR11172] (ab211996),Antibody target not in NF pathway/tumor biology gene list: S100A11
beta tubulin,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,beta tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"beta tubulin (Developmental Hybridoma Studies Bank, #E7, 1:10,000 dilution)",Generic reporter/tag/housekeeping antibody: beta tubulin
pMEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pMEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK (Cell Signaling Technologies, #9121, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pMEK
MEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,MEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total MEK (Cell Signaling Technologies, #8727, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: MEK
pPAK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,pPAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pPAK (Cell Signaling Technologies, #2601, 1:1000 dilution)",Antibody target not in NF pathway/tumor biology gene list: pPAK
Caspase-7,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,0.33,Low,,,,Caspase-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-7 (Cell Signaling Technologies, #9492, 1:1,000 dilution)",Antibody target not in NF pathway/tumor biology gene list: Caspase-7
Neurofilament,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,Neurofilament,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Neurofilament (1:1000; ab4680; Abcam),Antibody target not in NF pathway/tumor biology gene list: Neurofilament
Pan-TEAD,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,Pan-TEAD,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pan-TEAD (1:1000; #13295; CST),Antibody target not in NF pathway/tumor biology gene list: Pan-TEAD
CTGF,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,0.33,Low,,,,CTGF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CTGF (1:500, ab6992, Abcam)",Antibody target not in NF pathway/tumor biology gene list: CTGF
Notch1,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,Notch1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",Antibody target not in NF pathway/tumor biology gene list: Notch1
"Na+,K+-ATPase",antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,False,0.67,Low,,,,"Na+,K+-ATPase",Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)","Antibody target not in NF pathway/tumor biology gene list: Na+,K+-ATPase"
NeuroD1,antibodies,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,False,0.33,Low,,,,NeuroD1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",Antibody target not in NF pathway/tumor biology gene list: NeuroD1
Phospho-Rb Ser 780,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,False,0.67,Low,,,,Phospho-Rb Ser 780,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)",Antibody target not in NF pathway/tumor biology gene list: Phospho-Rb Ser 780
Gal α 1-3Gal,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,Experimental Usage,False,0.33,Low,,,,Gal α 1-3Gal,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS",Antibody target not in NF pathway/tumor biology gene list: Gal α 1-3Gal
DARPP32,antibodies,PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) | Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: DARPP32
p-MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,p-MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p-MAPK
total MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,0.33,Low,,,,total MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: total MAPK
p-DARPP32,antibodies,PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.33,Low,,,,p-DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies | Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",Antibody target not in NF pathway/tumor biology gene list: p-DARPP32
Cy3/Cy5,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,Cy3/Cy5,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 h at room temperature",Generic reporter/tag/housekeeping antibody: cy3/cy5
DAXX,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,False,1.00,Medium,,,,DAXX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies) was performed manually",Antibody target not in NF pathway/tumor biology gene list: DAXX
"HLA-A,B,C",antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,"HLA-A,B,C",,,,,,,,,,,,,,,,,,,,,,,,,,,,"following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)","Antibody target not in NF pathway/tumor biology gene list: HLA-A,B,C"
H-2,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,H-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody",Antibody target not in NF pathway/tumor biology gene list: H-2
human nuclei,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,0.33,Low,,,,human nuclei,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using the following antibodies: human nuclei (ab254080, Abcam)",Generic reporter/tag/housekeeping antibody: human nuclei
LAMA2,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,LAMA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)",Antibody target not in NF pathway/tumor biology gene list: LAMA2
SLC22A3,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,SLC22A3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)",Antibody target not in NF pathway/tumor biology gene list: SLC22A3
PRRX1,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,False,0.33,Low,,,,PRRX1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)",Antibody target not in NF pathway/tumor biology gene list: PRRX1
Phospho-p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,Phospho-p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,Antibody target not in NF pathway/tumor biology gene list: Phospho-p44/42 ERK1/2
p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,Antibody target not in NF pathway/tumor biology gene list: p44/42 ERK1/2
phosphor-p44/p42 MAPK (ERK1/2),antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,False,1.00,Medium,,,,phosphor-p44/p42 MAPK (ERK1/2),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Catalog #4370, Rabbit mAb, 1:100 dilution)",Antibody target not in NF pathway/tumor biology gene list: phosphor-p44/p42 MAPK (ERK1/2)
p-ERK1/2,antibodies,PMID:37681415 | PMID:24375753,10.1172/jci.insight.168445 | 10.1002/ana.24093,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,p-ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK1/2 (CST 4370, clone D13.14.4E) | pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",Antibody target not in NF pathway/tumor biology gene list: p-ERK1/2
c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz) | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",Antibody target not in NF pathway/tumor biology gene list: c-Met
phosphorylated c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,phosphorylated c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen)",Antibody target not in NF pathway/tumor biology gene list: phosphorylated c-Met
mesothelin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.33,Low,,,,mesothelin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz),Antibody target not in NF pathway/tumor biology gene list: mesothelin
phospho P-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,phospho P-Met,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: phospho P-Met
MAPK,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,0.33,Low,,,,MAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",Antibody target not in NF pathway/tumor biology gene list: MAPK
p55/MPP1,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.9,Development,False,1.00,Medium,,,,p55/MPP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected,Antibody target not in NF pathway/tumor biology gene list: p55/MPP1
NF-H,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,NF-H,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-NF-H (Chemicon); and mouse anti-Caspr,Antibody target not in NF pathway/tumor biology gene list: NF-H
Caspr,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,0.67,Low,,,,Caspr,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel",Antibody target not in NF pathway/tumor biology gene list: Caspr
CD11c,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD11c,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD11c
CD19,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD19
CD163,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CD163,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CD163
CSF1R,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,False,0.33,Low,,,,CSF1R,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",Antibody target not in NF pathway/tumor biology gene list: CSF1R
ColIA,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,0.67,Low,,,,ColIA,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA) | All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI",Antibody target not in NF pathway/tumor biology gene list: ColIA
Abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,Abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: Abl
c-abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,c-abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total c-abl protein was detected using an antibody from BD Biosciences (Cat. no. 554148, San Jose, CA, USA)",Antibody target not in NF pathway/tumor biology gene list: c-abl
TGF-β,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,0.33,Low,,,,TGF-β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer",Antibody target not in NF pathway/tumor biology gene list: TGF-β
MAP2,antibodies,PMID:25535838 | PMID:36241865,10.7554/eLife.05151 | 10.1038/s12276-022-00850-9,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,0.67,Low,,,,MAP2,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MAP2 (1:1000, mouse, Sigma-Aldrich) | Anti-MAP2 antibody primary IF and WB CST",Antibody target not in NF pathway/tumor biology gene list: MAP2
NF-200,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,NF-200,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NF-200 antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: NF-200
P-mTOR,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,P-mTOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-P-mTOR antibody primary WB CST,Antibody target not in NF pathway/tumor biology gene list: P-mTOR
Rictor,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,Rictor,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Rictor antibody primary WB CST,Antibody target not in NF pathway/tumor biology gene list: Rictor
bcl2,antibodies,PMID:32948135 | PMID:36241865,10.1186/s12885-020-07397-w | 10.1038/s12276-022-00850-9,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.95,Experimental Usage,False,1.00,Medium,,,,bcl2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO) | Anti-Bcl-2 antibody primary IF and WB CST",Antibody target not in NF pathway/tumor biology gene list: bcl2
myelin basic protein,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,0.33,Low,,,,myelin basic protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-myelin basic protein (MBP) antibody primary IF and WB CST,Antibody target not in NF pathway/tumor biology gene list: myelin basic protein
pErbB2,antibodies,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.33,Low,,,,pErbB2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,stained with pErbB2 (1∶50 dilution) as previously described [14],Antibody target not in NF pathway/tumor biology gene list: pErbB2
Calbindin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Calbindin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calbindin (1:1000, mouse, Sigma-Aldrich)",Antibody target not in NF pathway/tumor biology gene list: Calbindin
GABARα6,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,GABARα6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GABARα6 (1:500, rabbit, Millipore)",Antibody target not in NF pathway/tumor biology gene list: GABARα6
Tbr2,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Tbr2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tbr2 (1:1000, rabbit, Abcam)",Antibody target not in NF pathway/tumor biology gene list: Tbr2
Calretinin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,Calretinin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calretinin (1:1000, mouse, Millipore)",Antibody target not in NF pathway/tumor biology gene list: Calretinin
P27,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,P27,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P27 (1:250, rabbit, Santa Cruz Biotechnology, Dallas, TX)",Antibody target not in NF pathway/tumor biology gene list: P27
β-gal,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.67,Low,,,,β-gal,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-gal (1:1000, rabbit, 5 prime-3 prime, Gaithersburg, MD)",Generic reporter/tag/housekeeping antibody: β-gal
COL4A,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,COL4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"KI-67 (prediluted; catalog 790-4286, Ventana), and COL4A (1:1000 dilution; catalog ab6586, Abcam)",Antibody target not in NF pathway/tumor biology gene list: COL4A
histone H3 (tri methyl K27),antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,0.33,Low,,,,histone H3 (tri methyl K27),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunolabeling for anti-histone H3 (tri methyl K27) (1:200 dilution; catalog ab6002, Abcam)",Antibody target not in NF pathway/tumor biology gene list: histone H3 (tri methyl K27)
XBP1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: XBP1
XBP1u,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1u,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)",Antibody target not in NF pathway/tumor biology gene list: XBP1u
XBP1s,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,XBP1s,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-XBP1s (Cell Signaling),Antibody target not in NF pathway/tumor biology gene list: XBP1s
Parkin,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,Parkin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: Parkin
PINK1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,PINK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)",Antibody target not in NF pathway/tumor biology gene list: PINK1
ATP5H,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.33,Low,,,,ATP5H,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)",Antibody target not in NF pathway/tumor biology gene list: ATP5H
p21,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,p21,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)",Antibody target not in NF pathway/tumor biology gene list: p21
bcl6,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,False,1.00,Medium,,,,bcl6,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)",Antibody target not in NF pathway/tumor biology gene list: bcl6
phospho-RB1 S807/811,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.33,Low,,,,phospho-RB1 S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with phospho-RB1 S807/811 antibody (Cell Signaling Technology, no. 8516, 1:1600)",Antibody target not in NF pathway/tumor biology gene list: phospho-RB1 S807/811
kappa light chain,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,1.00,Medium,,,,kappa light chain,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"kappa light chain to identify plasma cells (rabbit monoclonal antibody, Sigma Aldrich, clone RM103, SAB5600201, 1:400)",Antibody target not in NF pathway/tumor biology gene list: kappa light chain
SIAH,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,,,,SIAH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody),Antibody target not in NF pathway/tumor biology gene list: SIAH
Ref-1,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,,,,Ref-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained for Ref-1 (mouse Ref-1 antibody, 1:200 dilution, Novus Biologicals, 13B8E5C2)",Antibody target not in NF pathway/tumor biology gene list: Ref-1
mCherry,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCherry,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-mCherry-WPRE-pA Addgene Plasmid#: 37119 RRID: Addgene_37119 Gift of Bernardo Sabatini,Generic reagent (fluorescent label / control / probe): mCherry
mRuby,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mRuby,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mRuby-WPRE Addgene Plasmid#: 99114 RRID: Addgene_99114,Generic reagent (fluorescent label / control / probe): mRuby
mTurquoise,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mTurquoise,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mTurquoise-WPRE Addgene Plasmid#: 99113 RRID: Addgene_99113,Generic reagent (fluorescent label / control / probe): mTurquoise
GFP,genetic_reagents,PMID:40590220 | PMID:31545171 | PMID:21072183 | PMID:39129390 | PMID:24509877 | PMID:20049725 | PMID:25043591,10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1371/journal.pone.0013791 | 10.1002/1878-0261.13704 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.1002/jbmr.2316,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC) | pAAV-Th-GFP-WPRE Addgene Plasmid#: 99128 RRID: Addgene_99128 | subcloned as a Bgl II/Xho I fragment into the retroviral expression vector pBMN-I-GFP | co‐transfected with the pl018 plasmid to express Cas9 and the sgRNA (CGCTTCTCCCTTGTCATATC) and pAct‐GFP plasmid | MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate | lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library) or GFP (Addgene) | containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)",Generic reagent (fluorescent label / control / probe): GFP
pCR2.1-TOPO,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCR2.1-TOPO,Plasmid,pCR2.1,,,,,,,,,,,,,,,,,,,The PCR products were cloned in the pCR2.1-TOPO-vector (Invitrogen) and transformed into TOP-10F' cells.,Generic reagent (fluorescent label / control / probe): pCR2.1-TOPO
eGFP,genetic_reagents,PMID:20200958 | PMID:21949590,10.1002/jbmr.42 | 10.2478/v10134-010-0025-8,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eGFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab) | Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine,Generic reagent (fluorescent label / control / probe): eGFP
oligo-dT,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,oligo-dT,Other,,,,,,,,,,,,,,,,,,,,"mRNA was selected by running total RNA over oligo-dT columns (Invitrogen, Carlsbad, CA)",Generic reagent (fluorescent label / control / probe): oligo-dT
sgRNA,genetic_reagents,PMID:38216572 | PMID:27956228 | PMID:35789380 | PMID:39415595,10.1038/s41467-024-44755-9 | 10.1053/j.gastro.2016.12.002 | 10.1158/2159-8290.CD-21-1671 | 10.1242/dmm.050862,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pCRISPRia-v2,,,,,,,,,,,,,,,,,,,"Subsequent gene specific knockdowns were achieved by individually cloning single-guide RNA (sgRNA) protospacer sequences into the pCRISPRia-v2 vector (#84832, Addgene) | sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230) or lentiV2 (addgene 52961) | Control and SUZ12 sgRNA targeting the VEFS functional domain were cloned into pL-CRISPR.EFS.Blast (plasmid was generated by replacing tagRFP in Addgene Plasmid #57819) | gRNAs targeting zebrafish nf2a/b were validated and cloned in the pU6(x):sgRNA#(x) vectors",Generic reagent (fluorescent label / control / probe): sgRNA
Cas9,genetic_reagents,PMID:39269317 | PMID:34415582 | PMID:34630515 | PMID:37164978 | PMID:32642733 | PMID:39129390 | PMID:39890807 | PMID:41036607 | PMID:41023593,10.1158/1078-0432.CCR-24-1750 | 10.1002/glia.24075 | 10.3389/fgene.2021.721045 | 10.1038/s41467-023-38432-6 | 10.1093/noajnl/vdz061 | 10.1002/1878-0261.13704 | 10.1038/s41598-024-84493-y | 10.1158/1535-7163.MCT-24-1053 | 10.1186/s10020-025-01353-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Viral,LentiCas9-Blast,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene | We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish | 1.95μm Cas9 (Cas9 Nuclease V3; IDT) | The injection solution contained gRNAs, S. pyogenes Cas9 mRNA (PNA Bio Inc., Thousand Oaks, CA or Millipore Sigma, Burlington, MA) | To generate CRISPR/Cas9-modified ipNF06.2A cell lines, sequences were subcloned into pX330 | pX330-U6-Chimeric_BB-CBh-HSpCas0 (Addgene) | WT S2R+ cells were co‐transfected with the pl018 plasmid to express Cas9 | we utilized CRISPR Cas9 targeting of NF1 exon 2 to create inactivating indels in NF1 on both alleles | One million cells were electroporated (1 pulse of 1400V for 30 ms) with 2 µg Flag-hCas9 | Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments",Generic reagent (fluorescent label / control / probe): Cas9
CRISPR-Cas9,genetic_reagents,PMID:39269317 | PMID:39129390 | PMID:35393510,10.1158/1078-0432.CCR-24-1750 | 10.1002/1878-0261.13704 | 10.1038/s41418-022-00991-4,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Viral,LentiCRISPR-v2,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene | NF1‐sg2 (ACACTGGAAAAATGTCTTGC), a sgRNA targeting human NF1 exon 3 in the lentiCRISPR v1 plasmid | Oligonucleotide pairs were annealed and cloned into the transfer plasmid lentiCRISPRv2 (Addgene, Watertown, MA, USA, #52961)",Generic reagent (fluorescent label / control / probe): CRISPR-Cas9
Guide RNA,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Guide RNA,Viral,LentiGuide-Puro,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene",Generic reagent (fluorescent label / control / probe): Guide RNA
Human All Exon capture probes,genetic_reagents,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon capture probes,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were generated from 1 μg genomic DNA using Agilent SureSelect Human All Exon kit (Agilent Technologies, California, USA)",Generic reagent (fluorescent label / control / probe): Human All Exon capture probes
Fluc and mCherry,genetic_reagents,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Fluc and mCherry,Viral,,,,,,,,,,,,,,,,,,,,These cell lines have been transduced with lentivirus expressing Fluc and mCherry genes as described previously,Generic reagent (fluorescent label / control / probe): Fluc and mCherry
empty vector,genetic_reagents,PMID:29715273 | PMID:32438526,10.1371/journal.pone.0196726 | 10.1002/lary.28671,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,empty vector,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,"An empty vector pcDNA3.1 was used as a control | Adenovirus (Ad) CMVempty vector (EV) at 5 × 109 pfu/mL, AdCMVNeuroD1 at 2 × 109 pfu/mL",Generic reagent (fluorescent label / control / probe): empty vector
Tet-On,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-On,Viral,pLVX,Tet-inducible,,,,,,,,,,,,,,,,,,in a modified pTight backbone (Clonetech) with pLVX-Tet-On doxycycline inducible vector (Clonetech),Generic reagent (fluorescent label / control / probe): Tet-On
AP-1 luciferase,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AP-1 luciferase,Plasmid,,AP-1,,,,,,,,,,,,,,,,,,Cells were transfected using FuGENE HD (Roche) with 100ng per well of an AP-1 luciferase (Stratagene) reporter vector,Generic reagent (fluorescent label / control / probe): AP-1 luciferase
pLKO.1,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pLKO.1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Lentivirus packaging, envelope and control non-hairpin (NHP) pLKO.1 plasmids (Addgene)",Generic reagent (fluorescent label / control / probe): pLKO.1
shRNA,genetic_reagents,PMID:35789380 | PMID:26219339 | PMID:23685747 | PMID:41023593 | PMID:25772366,10.1158/2159-8290.CD-21-1671 | 10.18632/oncotarget.4858 | 10.1038/ng.2641 | 10.1186/s10020-025-01353-9 | 10.1016/j.celrep.2015.02.041,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,LT3GEPIR,,,,,,,,,,,,,,,,,,,"Control (sh Ren.713), DNMT1, DNMT3A, and DNMT3B shRNAs were cloned into Tet-ON all-in-one plasmids LT3GEPIR (gift from Johannes Zuber, RRID:Addgene_111177) | 6,091 shRNAs, cloned into the pLKO-puromycin system | shRNA GIPZ lentiviral constructs were purchased from Openbiosystems | CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1 | Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected",Generic reagent (fluorescent label / control / probe): shRNA
Human All Exon,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon,Other,,,,,,,,,,,,,,,,,,,,We performed exome sequencing on five malignant meningiomas on the Illumina HiSeq2000 platform using Agilent SureSelect Human All Exon kits.,Generic reagent (fluorescent label / control / probe): Human All Exon
nuclear RFP,genetic_reagents,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nuclear RFP,Viral,,EF1α,,,,,,,,,,,,,,,,,,"Cell lines were transduced with Incucyte Nuclight Red Lentivirus (Sartorius, Gottingen, Germany) such that they will produce an EF1α promoter driven nuclear restricted red fluorescent label",Generic reagent (fluorescent label / control / probe): nuclear RFP
non-targeting control,genetic_reagents,PMID:20195187 | PMID:33032988,10.1097/MAO.0b013e3181d2777f | 10.1158/0008-5472.CAN-20-1365,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,non-targeting control,Other,,,,,,,,,,,,,,,,,,,,"Transfection with a non-targeting, random sequence siRNA (Dharmacon) or Lipofectamine ™ 2000 alone served as separate negative controls. | RNAi was performed using ON-TARGETplus Non-targeting Pool (#D-001810–10-05, Dharmacon)",Generic reagent (fluorescent label / control / probe): non-targeting control
firefly luciferase-GFP fusion,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-GFP fusion,Viral,,human ubiquitin-C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein,Generic reagent (fluorescent label / control / probe): firefly luciferase-GFP fusion
Tet-inducible,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-inducible,Viral,pLIX403,TRE3G,,,,,,,,,,,,,,,,,,the lentiviral attR1-attR2 Gateway destination vector pLIX403 (Addgene 41395) was modified to attR4-attR2 by Gibson assembly,Generic reagent (fluorescent label / control / probe): Tet-inducible
packaging,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,packaging,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260),Generic reagent (fluorescent label / control / probe): packaging
envelope,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,envelope,Plasmid,pMD2.G,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260) and pMD2.G (Addgene 12259) packaging plasmids,Generic reagent (fluorescent label / control / probe): envelope
DNA capture system,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA capture system,Other,,,,,,,,,,,,,,,,,,,,NGS was performed by oligonucleotide hybridization‐based DNA capture (SureSelect; Agilent),Generic reagent (fluorescent label / control / probe): DNA capture system
gRNA,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gRNA,Plasmid,,U6,,,,,,,,,,,,,,,,,,U6-gRNA vectors were produced as previously described and introduced into iHSCs that are proficient for NF1,Generic reagent (fluorescent label / control / probe): gRNA
Luciferase-IRES-GFP,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase-IRES-GFP,Transposon,,CAGG,,,,,,,,,,,,,,,,,,co-transposition was performed using 500 ng of the piggyBac (PB) transposon PB-CAGG-Luciferase-IRES-GFP-PGK-PuroR,Generic reagent (fluorescent label / control / probe): Luciferase-IRES-GFP
shRNAs,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNAs,Viral,,,,,,,,,,,,,,,,,,,,"We infected secondary Nf1 neurofibroma spheres or fl/fl;DhhCre Stat3 DRG/neurofibroma spheres with shRNAs and non-target control (Sigma, St Louis, MO, USA)",Generic reagent (fluorescent label / control / probe): shRNAs
NucLight red,genetic_reagents,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NucLight red,Viral,,,,,,,,,,,,,,,,,,,,Cell lines were infected with NucLight red lentivirus and stably selected in puromycin,Generic reagent (fluorescent label / control / probe): NucLight red
firefly luciferase-eGFP fusion,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-eGFP fusion,Viral,FUW,human ubiquitin C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein driven by the human ubiquitin C promoter,Generic reagent (fluorescent label / control / probe): firefly luciferase-eGFP fusion
Microsatellite markers,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Microsatellite markers,Other,,,,,,,,,,,,,,,,,,,,"Loss of heterozygosity (LOH) in 22q was investigated using microsatellites D22S420, D22S539, D22S1174, D22S315, D22S1154, D22S1163, D22S280, D22S277, D22S283, D22S423, D22S274, and D22S1169 from the ABI PRISM Linkage Mapping set version 2.5",Generic reagent (fluorescent label / control / probe): Microsatellite markers
Scramble,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scramble,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Scramble (TRC1/1.5; SHC002)—5′-CAACAAGATGAAGAGCACCAA-3′,Generic reagent (fluorescent label / control / probe): Scramble
Human Exome,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Exome,Other,,,,,,,,,,,,,,,,,,,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland) | Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland) or TruSeq Exome kit (Illumina, San Diego, CA)",Generic reagent (fluorescent label / control / probe): Human Exome
pcDNA3.1,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pcDNA3.1,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,"PCR amplicons were cloned into pcDNA3.1 vector (Life Technologies, CA, USA)",Generic reagent (fluorescent label / control / probe): pcDNA3.1
Scrambled siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scrambled siRNA,Other,,,,,,,,,,,,,,,,,,,,Scrambled oligonucleotides (Cat. no. sc-36869) or vehicle only was used as controls,Generic reagent (fluorescent label / control / probe): Scrambled siRNA
MSCV,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MSCV,Viral,,,,,,,,,,,,,,,,,,,,Murine stem cell virus (MSCV) infection was employed to express human WT or mutant (L64P patient mutation) merlin,Generic reagent (fluorescent label / control / probe): MSCV
PLKO,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PLKO,Viral,,,,,,,,,,,,,,,,,,,,PLKO virus was used as an empty vector control,Generic reagent (fluorescent label / control / probe): PLKO
